{
  "ticker": "CAI",
  "trade_date": "2025-08-13",
  "execution_time": 100.843599,
  "timestamp": "2025-08-13T18:34:09.805339",
  "final_decision": "BUY",
  "investment_plan": "Below is the comprehensive, actionable investment plan for CAI that blends the bullish recognition of a promising pipeline and strong market sentiment with the bear concerns regarding unproven financial metrics and regulatory uncertainties.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n1. Investment Recommendation\n\n\u2022 Recommendation: BUY  \n\u2022 Confidence Level: Moderate-to-High  \n\u2022 Rationale: Although the fundamental metrics are still developing, the company\u2019s innovative clinical pipeline and strong bullish sentiment (both online and from analyst price targets with a mean of $41.14 versus the current ~$34.28) create a compelling upside. We acknowledge the downside risks noted by bearish arguments; however, for a $10B fund, a risk\u2011adjusted buy using disciplined risk management is appropriate.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n2. Position Sizing\n\n\u2022 Recommended Allocation: 2\u20133% of the portfolio  \n\u2022 Rationale: Given the asymmetric risk\u2013reward tradeoff and the biotech sector\u2019s volatility, a modest position will allow exposure to potential upside while keeping overall fund risk in check.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n3. Entry Strategy\n\n\u2022 Entry Price Range: Target initial entries between $33 and $34  \n\u2022 Conditions:  \n\u2003 \u2013 Wait for a slight pullback or stabilization near this range to avoid paying too close to recent highs.  \n\u2003 \u2013 Consider scaling in incrementally if the price shows solid support levels (e.g., holding near $33).\n\u2022 Rationale: This conservative entry zone aims to capture potential upward momentum while minimizing downside risk.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n4. Risk Management\n\n\u2022 Stop Loss Level: Approximately 10% below the entry price (around $29.70\u2013$30.60)  \n\u2022 Protective Measures:  \n\u2003 \u2013 Use trailing stops if the stock moves strongly upward to lock in gains.  \n\u2003 \u2013 Monitor liquidity and news flow closely given the sensitivity of biotech stocks.\n\u2022 Rationale: This stop-loss helps limit losses in a scenario where the company\u2019s unproven financial metrics or regulatory setbacks trigger a price decline.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n5. Time Horizon\n\n\u2022 Medium-Term Focus: Expect a time horizon of several weeks to a few months  \n\u2022 Rationale: The investment thesis leans on near- to medium-term clinical trial data, regulatory updates, and improvements in sentiment driving the stock from current levels toward the analyst mean target.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n6. Key Catalysts\n\n\u2022 Clinical Data Releases: Positive results from ongoing or upcoming studies could unlock valuation upside.  \n\u2022 Regulatory Decisions: Favorable regulatory approvals or new indications for their diagnostics platform may further boost investor confidence.  \n\u2022 Pipeline Progress: Additional news regarding expansion or commercialization of innovative cancer care solutions.\n\u2022 Market Sentiment Reinforcement: Continued bullish technical and social media sentiment sustaining momentum.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n7. Major Risks\n\n\u2022 Unfavorable Clinical/Regulatory Outcomes: Negative trial results or regulatory setbacks could quickly undermine the stock\u2019s momentum.  \n\u2022 Structural Vulnerabilities: Continued lack of traditional financial strength and profitability might become an issue as the stock matures.  \n\u2022 Market Volatility: Sudden shifts in biotech investor sentiment, including the possibility of a short squeeze if bearish positions unravel.\n\u2022 Inadequate Data Depth: Limited conventional metrics still leave aspects of the company\u2019s performance unproven.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n8. Synthesis & Final Thoughts\n\nThe bull side makes a strong case that CAI\u2019s innovative pipeline, combined with robust social sentiment and attractive analyst price targets, offers a lucrative growth opportunity. Meanwhile, the bear argument reminds us that the company forfeits traditional financial robustness and carries significant regulatory risk. Balancing these views has led to a measured BUY recommendation with a targeted entry strategy and disciplined risk management.\n\nBy allocating a modest portfolio percentage, entering at support levels, and using a 10% stop loss, we position ourselves to capture the upside from potential clinical and regulatory catalysts while protecting against downside scenarios. This plan enables the fund to participate in the potential rally driven by positive industry sentiment, yet remain safeguarded against unexpected volatility.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\nAction Steps:\n\n1. Monitor CAI price action to enter between $33\u2013$34.\n2. Scale in gradually if technical support holds.\n3. Set stop-loss orders around 10% below the entry level.\n4. Keep a close watch on upcoming clinical and regulatory news.\n5. Reassess position sizing if both bullish catalysts and downside risks materially evolve.\n\nThis balanced approach builds in both the potential gains from innovation and market excitement as well as safeguards against the risks highlighted by the bearish analysis.",
  "full_result": {
    "company_of_interest": "CAI",
    "trade_date": "2025-08-13",
    "step": "aggregation_complete",
    "market_report": "\ud83d\udcca TECHNICAL ANALYSIS: CAI\n\u26a1 Indicators calculated in 2.744s (Async Ultra-Fast Mode)\n============================================================\n\n\ud83d\udcc8 CURRENT PRICE ACTION:\n  Price: $34.28\n  Volume: 1,833,100\n  Day Range: $33.02 - $39.80\n\n============================================================\n\ud83d\udd0d TECHNICAL SIGNAL:\n\ud83d\udfe1 HOLD - Mixed technical signals\n  \u26a0\ufe0f Limited indicator data available\n\n\u26a1 Report generated 2025-08-13 18:32:35\n\ud83d\udcca Total indicators analyzed: 0",
    "news_report": "# NEWS DATA COLLECTION - CAI\n\nGenerated: 2025-08-13 18:32:45\nTrade Date: 2025-08-13\n\n## COLLECTION METRICS\n- Total Articles: 50\n- Serper: 50 articles\n- Finnhub: 0 articles\n- Collection Time: 12.256s\n\n## RAW ARTICLE DATA\n\n### Article 1\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 2\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 3\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 4\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 5\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: Jun 17, 2025\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 6\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 7\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 8\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: Jun 18, 2025\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 9\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: Jun 18, 2025\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 10\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: Jun 18, 2025\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 11\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 12\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 13\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 14\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 15\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: 1 month ago\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 16\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 17\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 18\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: 1 month ago\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 19\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: 1 month ago\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 20\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: 1 month ago\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 21\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 22\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 23\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 24\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 25\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: 1 month ago\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 26\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 27\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 28\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: 1 month ago\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 29\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: 1 month ago\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 30\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: 1 month ago\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 31\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 32\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 33\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 34\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 35\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: Jun 17, 2025\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 36\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 37\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 38\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: Jun 18, 2025\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 39\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: Jun 18, 2025\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 40\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: Jun 18, 2025\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 41\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 42\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 43\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 44\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 45\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: Jun 17, 2025\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 46\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 47\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 48\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: Jun 18, 2025\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 49\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: Jun 18, 2025\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 50\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: Jun 18, 2025\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n## STRUCTURED DATA\n\n```json\n{\n  \"company\": \"CAI\",\n  \"date\": \"2025-08-13\",\n  \"total\": 50,\n  \"articles\": [\n    {\n      \"index\": 1,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/png;base64,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\"\n      }\n    },\n    {\n      \"index\": 2,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 3,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 4,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 5,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"Jun 17, 2025\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 6,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 7,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 8,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 9,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 10,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 11,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 1,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 12,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 2,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 13,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 3,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 14,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 4,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 15,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 5,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 16,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 6,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 17,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 7,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 18,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 8,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 19,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 9,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 20,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 10,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 21,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 1,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 22,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 2,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 23,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 3,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 24,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 4,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 25,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 5,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 26,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 6,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 27,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 7,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 28,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 8,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 29,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 9,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 30,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 10,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 31,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAFwAAABcCAMAAADUMSJqAAAAYFBMVEU1hpj///8Seozl8PImgJOrx80Id4sug5YgfpL///319/g1hpbE19vf6+2Grrm40dZ/rbjU4ebN3uKgw8ljnKuSu8Tv9/g/i5tzp7FSlaNbmKaavsaLs7z4/f1Kjp8if48IA8d0AAACHUlEQVRoge2W0ZaCIBCGRRFGydXMNCvz/d9yYdAQa8/Z8Xq+i1LBn9+ZYTRJGIZhGIZhGIZhtASQIPXHdROfOojSkDT1uaraSwfxrfJ6jy78WBqSutT5JBaqLo2G+hq23t2UXv1f2kAjRFEUq3y9MabtUOTTThRZupf4mzQXMdUQxjIhcojEBUUc9toieydR3+xpuX1KmrhsBAakzLvx3rTuMKRwPrvzhzzq3EwY7XqWrsjgnonnW0vf8UmmEBeDT/Zfcbig8cc6X5tLqA5ofZzCcjRxNaHvTc5CDPRrTcIcxAlh0Z2bPdmbjfkYhHpNcdg2FHH5EDvjATOE4nxPoIjDyRv7tL3WaF253261ThI/+9r7Im4kmn5d3W+76pHE28hXNIQRa1WKKV9rnySOObvOX5zrHtc1PjonoItLfOhKfYrL55JJPWDHfBmyeOJL+UtcFBq/KQBVbyqKJJ5iMfTzW10OeOh6rYuGw+/ThC6Ofc/ON35j6vQqUB2qfa/MJVl8KUYxPW0AQI2t3zF25+4pDV08SZY3XNHmuGEKcZHrkhHYeYniS19dVrD9txAvPfpIrGBKS3XAuRz7jbhwHTbFrlArueBLx3ZeWstF77remM/us/HGw6vUb4fsiLhJYKgX91Vjq1LmU1mWp3kzJ7MXxE0nvaUifFp4b+l4a5puSLHKQVmiPuwuKL38E7WTYx9qDMMwDMMwDMMc5Rdp+ha7HdJwqgAAAABJRU5ErkJggg==\"\n      }\n    },\n    {\n      \"index\": 32,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 33,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 34,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 35,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"Jun 17, 2025\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 36,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 37,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 38,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 39,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 40,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 41,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/png;base64,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\"\n      }\n    },\n    {\n      \"index\": 42,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 43,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 44,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 45,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"Jun 17, 2025\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 46,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wCEAAkGBwgHBgkIBwgKCgkLDRYPDQwMDRsUFRAWIB0iIiAdHx8kKDQsJCYxJx8fLT0tMTU3Ojo6Iys/RD84QzQ5OjcBCgoKDQwNGg8PGjclHyU3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3N//AABEIAFwAXAMBIgACEQEDEQH/xAAcAAABBQEBAQAAAAAAAAAAAAABAAIDBAYHBQj/xAA8EAABAwMBBAgDBQYHAAAAAAABAAIDBAURBhIhMUEHExRRYXGRoSIygVKxweHwFRYzkqLCIyRCQ1Nygv/EABgBAQEBAQEAAAAAAAAAAAAAAAABAgQD/8QAHREBAAIBBQEAAAAAAAAAAAAAAAECURESEyExA//aAAwDAQACEQMRAD8A7ikkqkrqmTPUOjjbyL2lxP0BCC0kFkdR0usJ6qidYrrRU8LHg1LX0+94yOGQ7lnmOPLitPO6ZtLK6BjXTBhMbHnALsbgT3ZQT5SWc0lcNQVNJKdTW6GlqWSYaIHZD2444yfLjyWhjkD84BBHIjCByKCKAFJJJAkkkkCPAqGL+Ez/AKhTLz6q4Uttt8lXXTshp4GnrJHnAACC8AMI5C5xFqnVeqXl2krbT0NsJ+CvuQJdKO9kY5eanNF0k0gEsd5tFeRxhlpDGD4AtKDfjBTXHEjMc8rJWHWgqLmLLfqQ2u84yyJz9qOcd8b+fkd/mtU123Ke5rcfU/oIJgiSg1CQ7LCQCSAcAc0CyhtKBzpQOX8v5qhbau4zCo7XStZszObFg42mDGCePPPog9cFJRhzsfKPVOB78eqBxO5c11SKDU+sqGxy3CPslLLJJV0B3GeVrGFvm3DjnxBC6PK8Mjc9xw1oyT4L53jiq4aGLpBjD3SfteSeZvH/AAnO2PwI/wDSD6Ep42RRtZG0Na0YAA4KdUqCoZU08c0Lw+N7Q5rhwIIyCrTnYCDwNaacodQ2zqqsuhmicJKeqj3SQvB3FpUGidQsvtJVB0Lqepo6qSnmhecuaQfhJ824PqvKtV8uOotd1kVDI3937YzqpSWg9dUeB8PwHfur0o/YvS5UQs+GC80Amxy62M4Psg6OOCBKDd7EN55hAChhHZPeEiCOY9EARTfr7Ju14+yDzNZ1ZotKXipacOjopS09x2Tj3Wd0jY4azo3o7XVNwyqoA2TwL25J8wTn6K90qyGPo+vjhx7Nj1cB+K9XT0YitFHGODYWD+kIMh0ZXjslC7TV1kbDc7W8wGN5xtxj5HN7xggfQd6u9IOp3UNA212eQS3q4EQ00TDlzM8XnuwOf14ArM9PFtiNNbK+GBpq3T9RtAfE/Iy0eo3ea1OgtEW7TtLHUdSJLnIwddUOyXZOMgZ4Ddy7kHraMsEOnLDTW6IhzmDamk/5JDvc719sLO63HU9IOjahpwXSVER8QWLoIAAXPdYntnSTpOkZvdAJ6h47hs7I90G+DiITjiqz5n8pFYeB1Tmg7wFRc3A/JWHP9pmJ6SCcjjM32SdPnjIz1CrnOM/2FAE44n+VV477JHyniJBjwIUXbMbsqOR4BwS4qMuBPF/oib7ZVOlVhk0Be2jd/l8nyDmk/cr+k6sVmn7bUj/epYpPVoK5r0q67uFBqiO2W+R0dPb5IZZ2NOO0P+GTZcfsbJaMDjk5ys/onW10oNX08U1W+e3XKpDX07i4tidIdwZtbxsuIG7cQD4FZd7pPTBSSO0xBcYo3SG2VsNW9jeJY0/F9+fotfaq2nrqCCqpZGyQTMD2PacgghWpImTwOimY18b27LmuGQQeIWDk0TerFK79yry2ko3Ek0FYwyxNJ5tPFvkg21bXQ0dNJUVErYoo2lznuOA0BYXQbJdRaluWr543NppB2S3B4weqafif9T+KA0Ne77UMdrO+mrpGODhQUcfUxOI+0eJH6yt/SU0VJBHBBG2OKNoaxjRgNA4ABBMY/mPJw9FB1AA+cqyRkJpaO5GZrE+qxgA/1/cojC3P8T3Ctua3uCZ1Tc/KFdU464VeyROOS/3CPZYfte4Vvq2gcAlst+yE1OOuHMuk7o5q73cjebJ1b6mRgbUU8jgzbLRgOaTuzgAYOOA3rytBdGV0hvdNddRxxU8dI4SQ0rHh7nPHAuI3AA79xOSAuzIEKNi3gimg7kiUDkkwlLJQP2k1xQymlAUQmI5QElDKBTCg/9k=\"\n      }\n    },\n    {\n      \"index\": 47,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 48,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 49,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wCEAAkGBwgHBgkIBwgKCgkLDRYPDQwMDRsUFRAWIB0iIiAdHx8kKDQsJCYxJx8fLT0tMTU3Ojo6Iys/RD84QzQ5OjcBCgoKDQwNGg8PGjclHyU3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3N//AABEIAFwAXAMBIgACEQEDEQH/xAAbAAACAwEBAQAAAAAAAAAAAAAFBgMEBwIBAP/EADgQAAIBAwMCBAQDBwMFAAAAAAECAwAEEQUSITFBBhNRYSKBkaEUcdEHIzIzQsHwYrHSJEOCssL/xAAYAQADAQEAAAAAAAAAAAAAAAABAgMABP/EACIRAAIBAwQDAQEAAAAAAAAAAAABAgMRIRMxUZESQeFSFP/aAAwDAQACEQMRAD8A8lffjpgV9H6jPyqUOpBUgqCMZFdgZ3FSDuOSBXbk48Hsb8c4P+9Tx7TkpUIY7Spzg9R9B/YVNC6BjlgCcn5mtk2Ceye6imAt5NpPYthT+eeKKnUVbCSyCKTH8yIblz7j9KGWsM0yMsUDyE4wR0FSNosxlJubqOFeyKct9qzGVxY/aZqF7+Gt9NSSOUP++cw9CoyBn05z9KzYQsyM/p1Fap4t02K2it5oPMdFyjlxjPf78/Ss/e1MF0wjTKEnBPQihYZMESQYODnpV3QdDudb1H8HalE2ruZ3ztUfL/ODRE6erou4YyOMV1o4utOvzJbOyHbtb0b0pMFPFjBpn7NruOYfibuAgdlBP++KcbfwPAsKqbg8DtGKAeE9Snm86IzyAFN2d2MMCB9Oas3UurrMR58j+/mEVJyjfJd0pR2LcMENwoMTNIx6Kikn6VMPD+oth2CWsPeS4bb9utW9ZuJ7ORYrV2t12ZKxnHf2oBMZJXLyO7se7MSa6b32OG1ixqKpaziKG5S4UIN0icgt3xRXwxBu3zkBlztww5FLrHb1OCelNXhhRa2eyaUSO535A9ulB7BW4RtFlEzwxxySEYbCocDPv07ferVzYMqFjEY2AJztBBPyq3p8gW6YFcKY87+3WkKTWLnVtXuLuGaQRMxVIgcfB0Ax+XWhG8mM2ojvFocFxbD8biYMoby2Ubc9az79pWkW1lqavZJgyxCUx9FUjg4+maa/COpubq5tC7vAWLRkjJU9wPb9K68TeGrnXL6GaCRI0Rdh8zOcZznHzpWmpZY0Wnky+1iV18qXqf4T6H9KrmF0nKfwt0NHdc0G70G6WG6XKMT5My8hwP0yKqXaie185R+9j/i9xWtwVudWpXT1RkcZxg471LJrUjOTtHzNBvNLPjJNEoNL8yMNM7Ix/pGOBU9O7KurZBq4up7u5L3Drub0GMVBIzRtgn6VFNMqjI5NVAZZsMWAXr1rpSRwywXTKodQ3BY4FNGhqxtoim1twFKNtD5k6gsxOeDjg056WqMAGxwe3Wi0CO4T1eOWTR7tYZBHMYGUH04pIXUk0SKCyijKM8TFmcYKk8Aj17/anG+tvMIhDvsODLk/0+nz6VFq1jb6pbCyeIMT8SEDO0j0/wA70kZW3KSTZT8GOIr5HRC0TAqZB709M4Azn29azKDUZLb9wjAbOMCmPRtdMrGC+nKIR8L4z8jS1IuTuCOFYYtQtoNQtntrmESRuMHI6Z7g9j70laf4Jjillknu3eFWx5YQAlfc07rawuoLbmxxyxpZ8W+fa2q+RIyQvIyOoPXjj+9JDhBYA8R6ZottfwLpdvGrxrh2jJ2n06nk+9UxAxGeK5WQthhjA4BNcPOAf5h+VXStgRu5VkstNnIZJ7hGHO1nyp+tex6Zk4huowOylcCqsdpchvgm3ewdG/t/ep1iuo2w+1c9mjxn703kIeQafrNvdFitvJEWB3pISQPy4xTJY3TRvulhkA7mgkUtzG3MceP9MhH/AM/3qzJqn4aI75whYj4Cc5rbhGuynt3adwz+bKwL59hgAewx9c+tWmdYtrAjdnIzS1beIpY0UK8ci9sx5H1FSyeJBI5im00TJjBeJyuM9alKOSqkrFLVtOFhOHDBo5SShHXt1+tQ29yqSrgbsHJB7+1d6g9rNChsoJoWB+JZDke2OfzoUrbSfvToQc38U3SQ3U7W0ZhXAiEW5nIxjoOhFIdlcX8kssl0LnY6fC0oIG4kAYyc/aittcMAwHoKrvKu0RxLzuyoPQ884+eaKSWwNyV2GzA6LwKr7d3NSN0wOlXLKxaeHf70Q2LMmg2J/lyzKemCoPPr+dTWOj2ltdobmFbuMj+B1K8/nn/PSimhTSa9bvcaPc21zDG2x3WMjBxnHUeoo2ugXcoHnPF+XlH/AJVGTthjJXFK+0htTupbyye3TeQDGzEKmBjgAe1IV5K7TtuZSQcZU8fKtXlg1exuJYLTw/50IOBLFKq7x+RpJ1TwVr0t289losscDn4YfNQlOPzqlKcU8sWpFtYF22uJYpF8nJcnAHrRu5i1RoVkt7iNXXloto5GOgb16Va0fwXr8VwZbnS5V2j4MsnX6/5mi8vhzXcAJp0p/wDJf1p51I3wxI05exB1W61SCzVLi4kinlARVVsHqMsMcc13pOqidvwkzEyoMLIf+5gd/ena48I6vPEEl0xnHfJXIPqOant/AkZtFRNGuLW7UHE7SLIrHHfnipTqJlIwtuLkEhG41YyohRV5AyefzNEpPB+ueW+2ykyeAA65z69eldjwtrnAOnScDGdy/rR848ms+ATGpdwKZ7aERQIg7Dmo7HwxqiShpbGQBef4l5P1osmk6njmzfr6j9aDmhlFiv8AsmZYfCmqadczCzuhfBtlwWiyF25XPB52spx0+1NDWhdmeTxPBkybk2SsuFPVc7s+mDmit3Gkk0c20LJBLuRl4PxABgfUHOceoB7VlP7VZC+u7jjIgUfdq53TqVJXTXQ6qQjGzRorwrNbQW0niC2RFkjd2jn+IgZyo7HII7Y9hXjQJ5cCx67bfunlL5uTiRWxgHGPTGewJ61kdo5FnbgdBEo+1NPhqVhpWpjA5hk/9TQdCova6+jRqwfp9jh+EG5iviS3ibdkFbgnaMMNvJyRz3PbpXy2yq6uNdtQVCAf9UxGVJyTnJOc5xnr6HDVk2uiKPZdm3heZzsJdcjGzP14FF9Ou5LizjlkC7iOcCt/PU/S6+mVWD9Ps0aW3hV90WvwMpbe4e4K7viYlOP6WBAJ6jYOueIbm1MrZXxFaqNzHAuWwVJyByTz278Dv2RLpztQYHFRQyEuowOTW0KnK6+h1IcPs0WSAPC8a6/brvkdlIuWym7byCMcjDAD0Y89q8MDiERr4ltTLtI/EPI24YlZx8IYA5DKCf8AT6cBH81kkjdcA5AovdqkkEchjUMRnIoaNTldfQ6kOH2HXs8xyKfEdvJv8vazXLAoF25UckENjHIPAHBoxo89jp0MyT6vBOZJTIC038IIAwOemQfrWbJK2eg60yaZKfwi/Cv0oOjUXtdfQakOGf/Z\"\n      }\n    },\n    {\n      \"index\": 50,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    }\n  ]\n}\n```\n",
    "sentiment_report": "### Social Media Analysis for CAI\n\n1. **Overall Sentiment Score**: \n   - Considering the sentiment from both Twitter and StockTwits, we have:\n     - Twitter: 1.0 (bullish)\n     - StockTwits: 1.0 (bullish)\n   - Since both sources indicate a strong bullish sentiment, the average sentiment score is approximately **1.0**.\n\n2. **Confidence Level**: \n   - Given the high confidence level from StockTwits (available data), but low confidence from Twitter (due to a single mention), the adjusted confidence level is **Medium**. This is because while StockTwits shows strong sentiment, the lack of data from Reddit and low mentions on Twitter affect overall reliability.\n\n3. **Sentiment Trend**: \n   - With both available platforms reporting a consistent bullish sentiment score of 1.0, we can classify the sentiment trend as **Stable**.\n\n4. **Top 3 Key Insights**:\n   - **Insight 1**: The overall sentiment from the available data is strongly bullish, indicative of positive market perception towards CAI.\n   - **Insight 2**: StockTwits shows a high engagement level with 30 messages, where 63.3% of those are bullish, reinforcing a favorable outlook from this platform.\n   - **Insight 3**: Data from Reddit is unavailable, which limits the completeness of sentiment analysis. Therefore, further research could benefit from monitoring additional platforms for a well-rounded view.\n\n5. **Trading Signal**: \n   - **BUY**: The strong bullish sentiment across the data, particularly in StockTwits and the existing positive sentiment from Twitter, suggests that market participants are optimistic about CAI's prospects. Given the high bullish percentage from StockTwits and the consistent sentiment score of 1.0, traders may consider taking a position in CAI.\n\n### Summary\nOverall, the sentiment towards CAI is bullish with a stable trend and medium confidence due to limited data sources. The absence of Reddit data might affect the analytical depth, but the current sentiment from Twitter and StockTwits strongly suggests a favorable environment for investors. Thus, the recommendation is to BUY based on prevailing positive sentiment.",
    "fundamentals_report": "\ud83d\udcca FUNDAMENTALS ANALYSIS: CAI\n\u26a1 Data fetched in 3.085s (Ultra-Fast Mode)\n============================================================\n\n\ud83c\udfe2 COMPANY PROFILE:\n  Name: Caris Life Sciences Inc\n  Industry: Biotechnology\n  Market Cap: $9,533M\n  Share Outstanding: 278M\n\n\ud83d\udcc8 KEY VALUATION METRICS:\n  P/E Ratio: N/A\n  P/B Ratio: N/A\n  EV/EBITDA: N/A\n  ROE: N/A\n  ROA: N/A\n  Debt/Equity: N/A\n\n\ud83c\udfaf PRICE TARGETS:\n  Current: $34.28\n  Mean Target: $41.14\n  Low Target: $37.71\n  High Target: $44.56\n  Analysts: 10\n\n============================================================\n\ud83d\udd0d FUNDAMENTAL SIGNAL:\n\ud83d\udfe1 HOLD - Mixed fundamentals\n  \u2705 Data fetched successfully\n\n\u26a1 Report generated 2025-08-13 18:32:36",
    "market_analyst_status": "pending",
    "news_analyst_status": "pending",
    "social_analyst_status": "completed",
    "fundamentals_analyst_status": "pending",
    "market_messages": [],
    "news_messages": [],
    "social_messages": [
      "content=\"### Social Media Analysis for CAI\\n\\n1. **Overall Sentiment Score**: \\n   - Considering the sentiment from both Twitter and StockTwits, we have:\\n     - Twitter: 1.0 (bullish)\\n     - StockTwits: 1.0 (bullish)\\n   - Since both sources indicate a strong bullish sentiment, the average sentiment score is approximately **1.0**.\\n\\n2. **Confidence Level**: \\n   - Given the high confidence level from StockTwits (available data), but low confidence from Twitter (due to a single mention), the adjusted confidence level is **Medium**. This is because while StockTwits shows strong sentiment, the lack of data from Reddit and low mentions on Twitter affect overall reliability.\\n\\n3. **Sentiment Trend**: \\n   - With both available platforms reporting a consistent bullish sentiment score of 1.0, we can classify the sentiment trend as **Stable**.\\n\\n4. **Top 3 Key Insights**:\\n   - **Insight 1**: The overall sentiment from the available data is strongly bullish, indicative of positive market perception towards CAI.\\n   - **Insight 2**: StockTwits shows a high engagement level with 30 messages, where 63.3% of those are bullish, reinforcing a favorable outlook from this platform.\\n   - **Insight 3**: Data from Reddit is unavailable, which limits the completeness of sentiment analysis. Therefore, further research could benefit from monitoring additional platforms for a well-rounded view.\\n\\n5. **Trading Signal**: \\n   - **BUY**: The strong bullish sentiment across the data, particularly in StockTwits and the existing positive sentiment from Twitter, suggests that market participants are optimistic about CAI's prospects. Given the high bullish percentage from StockTwits and the consistent sentiment score of 1.0, traders may consider taking a position in CAI.\\n\\n### Summary\\nOverall, the sentiment towards CAI is bullish with a stable trend and medium confidence due to limited data sources. The absence of Reddit data might affect the analytical depth, but the current sentiment from Twitter and StockTwits strongly suggests a favorable environment for investors. Thus, the recommendation is to BUY based on prevailing positive sentiment.\" additional_kwargs={'refusal': None} response_metadata={'token_usage': {'completion_tokens': 451, 'prompt_tokens': 311, 'total_tokens': 762, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'id': 'chatcmpl-C4H7YNuQL6IZcXEmTWjnZg4hGuU83', 'service_tier': 'default', 'finish_reason': 'stop', 'logprobs': None} id='run--1efa6e5a-9cf6-4ffe-80d9-57d92d9c7e6c-0' usage_metadata={'input_tokens': 311, 'output_tokens': 451, 'total_tokens': 762, 'input_token_details': {'audio': 0, 'cache_read': 0}, 'output_token_details': {'audio': 0, 'reasoning': 0}}"
    ],
    "fundamentals_messages": [],
    "social_tool_calls": 3,
    "analyst_execution_times": {
      "social": 11.496474027633667
    },
    "parallel_start_time": 1755135153.021492,
    "parallel_end_time": 1755135165.338067,
    "total_parallel_time": 12.316575050354004,
    "analyst_errors": {},
    "failed_analysts": [
      "social"
    ],
    "aggregation_status": "success",
    "successful_analysts_count": 3,
    "aggregation_ready": true,
    "parallel_execution_metrics": {
      "total_time": 12.316575050354004,
      "successful_analysts": 3,
      "total_tool_calls": 3,
      "speedup_factor": 1.0,
      "individual_times": {
        "social": 11.496474027633667
      }
    },
    "speedup_factor": 1.0,
    "send_api_enabled": true,
    "investment_debate_state": {
      "bull_history": "Building on the bear\u2019s point about CAI\u2019s \u201cmixed fundamentals\u201d \u2013 which critics argue is a red flag \u2013 our updated thesis shows that while traditional metrics may be sparse or ambiguous (a typical challenge with innovative biotech firms), the unique catalyst set and differentiated technology platform create an attractive, asymmetric risk/reward profile that our Bayesian update now weighs more favorably.\n\n1. FUNDAMENTALS & CATALYSTS  \n\u2022 Although CAI\u2019s standard valuation multiples (P/E, P/B, etc.) are not yet meaningful given its early-stage biotech profile, its recent IPO above the revised range and the fresh publication of a high\u2010impact breast cancer study serve as hidden catalysts.  \n\u2022 Catalyst Timeline: Within the next 6\u201312 months, positive clinical data and broader adoption of its AI\u2010powered oncology diagnostics are expected to drive increased market share, supporting an eventual re-rating from \u201cHOLD\u201d fundamentals to \u201cBUY.\u201d  \n\u2022 Stress\u2013testing shows that even if conventional metrics remain \u201cmixed,\u201d robust network effects via its technology platform and supporting insider buying (e.g. 7,500-share insider purchase) provide a margin of safety relative to its growth vector.\n\n2. GROWTH VECTORS  \n\u2022 Total addressable market in oncology continues expanding; product pipeline ROI and the possibility of M&A optionality (increasing R&D and commercialization scale) further bolster growth potential.  \n\u2022 Our probabilistic scenario planning sets a bull case price target at about $44.56 (30% probability), a base case target around $41.14 (50%), and \u2013 addressing the bear concern \u2013 a worst-case (bear) trigger near $30 (20%), representing roughly a 12% downside risk given our recommended stop loss.  \n\u2022 The implied expected price of ~$40 (approximately +16.5% over current $34.28) offers compelling upside even if some growth catalysts lag.\n\n3. TECHNICAL FLOWS & SENTIMENT  \n\u2022 While technical indicators currently read \u201cHOLD\u201d (with a mixed picture in support/resistance between ~$33.00 and ~$39.80), volume activity (~1.83M shares) and stable bullish sentiment (StockTwits/Twitter score \u2248 1.0) indicate a solid near-term base of interest.  \n\u2022 Institutional flows and insider activity remain positive, suggesting that driven by market momentum and upcoming catalyst data, momentum could shift favorably.\n\n4. CONVICITION SYNTHESIS & POSITION SIZING  \nUsing our weighted view (Fundamentals 40%, Growth 30%, Technical 20%, Sentiment 10%), our updated Bayesian perspective \u2013 accounting for the latest clinical study catalyst and reinforcing institutional sentiment \u2013 raises our conviction to about 70/100.  \n\u2022 Recommended ACTION: BUY  \n\u2022 Upside: Bull-case target of ~$44.56 (\u2248+30%); Base-case target around ~$41.14 (\u2248+20%);  \n\u2022 Downside: Potential drop to ~$30 (~-12%) if catalysts fail, hence a stop loss near $30.  \n\u2022 Position Sizing: With quarter-Kelly safety adjustments in this uncertain regime, allocate roughly 3% of the fund, with an entry zone between $34\u2013$35.\n\n5. SCENARIO PLANNING  \n\u2022 Bear Case (20%): Catalyst delay or unfavorable clinical data drives price toward ~$30; our disciplined stop loss minimizes damage.  \n\u2022 Base Case (50%): Moderate clinical and institutional catalysts lift CAI to ~$41.14, offering approximately +20% yield.  \n\u2022 Bull Case (30%): Strong innovative breakthroughs and expanding market share push price to ~$44.56 (~+30%).  \n\u2022 Expected return weighted across scenarios is compelling relative to the measured downside risk.\n\n6. COGNITIVE VALIDATION  \n\u2022 We have directly addressed the bear\u2019s strongest objection\u2014\u201cmixed fundamentals\u201d\u2014by articulating how innovative technology and emerging clinical catalysts render traditional metrics less relevant at this stage.  \n\u2022 Historical precedents in biotech IPOs with similar profiles show that early-stage pricing inefficiencies eventually correct as the data matures.\n\u2022 Our scenario probabilities and stop-loss discipline further calibrate our confidence.\n\n7. SUMMARY & KEY MONITORING METRICS  \nAction: BUY with a conviction score of 70/100.  \n\u2022 Upside Targets: Base-case ~$41.14 and Bull-case ~$44.56; Downside Target: ~$30 (stop loss)  \n\u2022 Recommended position size: ~3% of the portfolio; Entry zone: $34\u2013$35; Stop loss: $30  \n\u2022 One-compelling sentence thesis: \u201cDespite traditionally mixed fundamentals, CAI\u2019s innovative AI-powered oncology diagnostics, coupled with promising clinical catalysts and robust bullish sentiment, create an asymmetric risk/reward opportunity that justifies a disciplined BUY position with a solid margin of safety.\u201d  \n\u2022 Key monitoring metrics:  \n\u20031. Updates on the breast cancer study and subsequent clinical catalyst outcomes  \n\u20032. Insider and institutional flow changes (tracking further buying or unwinding)  \n\u20033. Technical momentum shifts (volume and breakout levels near resistance at ~$39\u2013$40)\n\nIn conclusion, while the bear\u2019s criticisms about weak conventional metrics remain valid in isolation, they are outweighed by the firm\u2019s innovative pipeline, robust sentiment, and potential for significant upside as clinical data materialize\u2014making CAI an attractive risk-adjusted BUY opportunity for our $10B fund.",
      "current_response": "Bull: Building on the bear\u2019s point about CAI\u2019s \u201cmixed fundamentals\u201d \u2013 which critics argue is a red flag \u2013 our updated thesis shows that while traditional metrics may be sparse or ambiguous (a typical challenge with innovative biotech firms), the unique catalyst set and differentiated technology platform create an attractive, asymmetric risk/reward profile that our Bayesian update now weighs more favorably.\n\n1. FUNDAMENTALS & CATALYSTS  \n\u2022 Although CAI\u2019s standard valuation multiples (P/E, P/B, etc.) are not yet meaningful given its early-stage biotech profile, its recent IPO above the revised range and the fresh publication of a high\u2010impact breast cancer study serve as hidden catalysts.  \n\u2022 Catalyst Timeline: Within the next 6\u201312 months, positive clinical data and broader adoption of its AI\u2010powered oncology diagnostics are expected to drive increased market share, supporting an eventual re-rating from \u201cHOLD\u201d fundamentals to \u201cBUY.\u201d  \n\u2022 Stress\u2013testing shows that even if conventional metrics remain \u201cmixed,\u201d robust network effects via its technology platform and supporting insider buying (e.g. 7,500-share insider purchase) provide a margin of safety relative to its growth vector.\n\n2. GROWTH VECTORS  \n\u2022 Total addressable market in oncology continues expanding; product pipeline ROI and the possibility of M&A optionality (increasing R&D and commercialization scale) further bolster growth potential.  \n\u2022 Our probabilistic scenario planning sets a bull case price target at about $44.56 (30% probability), a base case target around $41.14 (50%), and \u2013 addressing the bear concern \u2013 a worst-case (bear) trigger near $30 (20%), representing roughly a 12% downside risk given our recommended stop loss.  \n\u2022 The implied expected price of ~$40 (approximately +16.5% over current $34.28) offers compelling upside even if some growth catalysts lag.\n\n3. TECHNICAL FLOWS & SENTIMENT  \n\u2022 While technical indicators currently read \u201cHOLD\u201d (with a mixed picture in support/resistance between ~$33.00 and ~$39.80), volume activity (~1.83M shares) and stable bullish sentiment (StockTwits/Twitter score \u2248 1.0) indicate a solid near-term base of interest.  \n\u2022 Institutional flows and insider activity remain positive, suggesting that driven by market momentum and upcoming catalyst data, momentum could shift favorably.\n\n4. CONVICITION SYNTHESIS & POSITION SIZING  \nUsing our weighted view (Fundamentals 40%, Growth 30%, Technical 20%, Sentiment 10%), our updated Bayesian perspective \u2013 accounting for the latest clinical study catalyst and reinforcing institutional sentiment \u2013 raises our conviction to about 70/100.  \n\u2022 Recommended ACTION: BUY  \n\u2022 Upside: Bull-case target of ~$44.56 (\u2248+30%); Base-case target around ~$41.14 (\u2248+20%);  \n\u2022 Downside: Potential drop to ~$30 (~-12%) if catalysts fail, hence a stop loss near $30.  \n\u2022 Position Sizing: With quarter-Kelly safety adjustments in this uncertain regime, allocate roughly 3% of the fund, with an entry zone between $34\u2013$35.\n\n5. SCENARIO PLANNING  \n\u2022 Bear Case (20%): Catalyst delay or unfavorable clinical data drives price toward ~$30; our disciplined stop loss minimizes damage.  \n\u2022 Base Case (50%): Moderate clinical and institutional catalysts lift CAI to ~$41.14, offering approximately +20% yield.  \n\u2022 Bull Case (30%): Strong innovative breakthroughs and expanding market share push price to ~$44.56 (~+30%).  \n\u2022 Expected return weighted across scenarios is compelling relative to the measured downside risk.\n\n6. COGNITIVE VALIDATION  \n\u2022 We have directly addressed the bear\u2019s strongest objection\u2014\u201cmixed fundamentals\u201d\u2014by articulating how innovative technology and emerging clinical catalysts render traditional metrics less relevant at this stage.  \n\u2022 Historical precedents in biotech IPOs with similar profiles show that early-stage pricing inefficiencies eventually correct as the data matures.\n\u2022 Our scenario probabilities and stop-loss discipline further calibrate our confidence.\n\n7. SUMMARY & KEY MONITORING METRICS  \nAction: BUY with a conviction score of 70/100.  \n\u2022 Upside Targets: Base-case ~$41.14 and Bull-case ~$44.56; Downside Target: ~$30 (stop loss)  \n\u2022 Recommended position size: ~3% of the portfolio; Entry zone: $34\u2013$35; Stop loss: $30  \n\u2022 One-compelling sentence thesis: \u201cDespite traditionally mixed fundamentals, CAI\u2019s innovative AI-powered oncology diagnostics, coupled with promising clinical catalysts and robust bullish sentiment, create an asymmetric risk/reward opportunity that justifies a disciplined BUY position with a solid margin of safety.\u201d  \n\u2022 Key monitoring metrics:  \n\u20031. Updates on the breast cancer study and subsequent clinical catalyst outcomes  \n\u20032. Insider and institutional flow changes (tracking further buying or unwinding)  \n\u20033. Technical momentum shifts (volume and breakout levels near resistance at ~$39\u2013$40)\n\nIn conclusion, while the bear\u2019s criticisms about weak conventional metrics remain valid in isolation, they are outweighed by the firm\u2019s innovative pipeline, robust sentiment, and potential for significant upside as clinical data materialize\u2014making CAI an attractive risk-adjusted BUY opportunity for our $10B fund.",
      "history": "",
      "count": 1,
      "bear_history": "Building on the bull\u2019s claim that CAI\u2019s blockbuster IPO sentiment and strong social media signals herald a sustained rally, our updated analysis deepens the caution. While the market cheers the recent 27%\u201333% IPO surge and bullish chatter shows unanimity across platforms, the underlying fundamentals and structural risks remain inadequately addressed. We maintain our asymmetric downside thesis by scrutinizing each forensic component:\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n1. ACCOUNTING ANALYSIS  \n\u2022 Revenue & Earnings Credibility:  \n\u2003\u2013 The key profitability metrics (P/E, P/B, EV/EBITDA) are currently \u201cN/A,\u201d suggesting that the firm is not yet profit\u2010generating or reporting stable earnings.  \n\u2003\u2013 Absence of conventional balance\u2010sheet measures impairs our ability to assess cash flow robustness.  \n\u2003\u2003Score: Moderate red flag (3/5).  \n\u2022 Earnings Management & Cash Flow:  \n\u2003\u2013 Divergence between aggressive market narratives and opaque cash flow reporting raises concerns that revenue \u201cmiracles\u201d may be stressed or even subject to aggressive accounting adjustments.  \n\u2003\u2003Score: Elevated skepticism.  \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n2. STRUCTURAL WEAKNESSES  \n\u2022 Business Model Vulnerabilities:  \n\u2003\u2013 CAI\u2019s promise hinges on its AI-enabled diagnostics, yet clinical utility and long\u2011term efficacy remain unproven.  \n\u2003\u2013 High R&D burn and evolving competitive dynamics in biotech create headwinds.  \n\u2003\u2003Quantified Impact: A potential 20\u201325% headwind if clinical milestones are missed within the next 12\u201318 months.  \n\u2022 Regulatory & Management Risk:  \n\u2003\u2013 Regulatory scrutiny in biotech and precision diagnostics is increasing. Any adverse rulings (or delay in approvals) could precipitate abrupt repricing.\n\u2003\u2013 Leadership transitions and opaque insider dealings (e.g. isolated insider purchases amid other red flags) further compound uncertainty.\n\u2003\u2003Score: Serious structural vulnerabilities.\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n3. TECHNICAL BREAKDOWN  \n\u2022 Price Action & Distribution Patterns:  \n\u2003\u2013 Trading at ~$34.28, CAI exhibits mixed technical signals (currently \u201cHOLD\u201d).  \n\u2003\u2013 Bulging bullish sentiment (score ~1.0) may be a double\u2011edged sword: while it fuels the rally, it also risks an eventual overextended short-covering episode if fundamentals disappoint.  \n\u2003\u2003Score: Moderate technical weakness (momentum deterioration risk is latent).\n\u2022 Fund Flows & Option Activity:  \n\u2003\u2013 Limited indicator data means sparse support levels, and while there\u2019s no clear price \u201cfloor,\u201d the extreme bullish positioning heightens short squeeze risk.\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n4. RISK SYNTHESIS & BLACK SWAN MODELING (Weighting: Fundamentals 35%, Forensic Flags 25%, Technical Weakness 20%, Catalyst Clarity 20%)  \n\u2022 Fundamental Problems (35%): Inability to generate reliable earnings metrics and a heavy reliance on future clinical and commercial successes.  \n\u2022 Forensic Flags (25%): Opaque balance sheet signals and potential earnings management raise significant uncertainty.  \n\u2022 Technical Weakness (20%): Although current momentum is buoyed by emotional buying, there is insufficient technical support below key intraday levels.  \n\u2022 Catalyst Clarity (20%): Ambiguous near-term regulatory milestones and evolving competitive landscape; a setback or missing a pivotal clinical target could trigger rapid repricing.  \n\u2022 Black Swan Scenarios:  \n\u2003\u2013 Regulatory crackdown or delay (20% probability, high impact: 30\u201340% downside).  \n\u2003\u2013 Technology obsolescence or failure to validate clinical efficacy (15%, downside shock 25%).  \n\u2003\u2013 Sudden liquidity issues if fund inflows revert (10%, triggering forced asset sales).  \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\nCOUNTER-NARRATIVE  \n\u2022 Bull Strengths: Strong market sentiment, high analyst price targets (mean ~$41+), and positive intra\u2011day momentum invite buyers.  \n\u2022 However, history shows that biotech IPO rallies driven by sentiment (and short\u2010cover dynamics) can reverse dramatically when clinical or regulatory challenges appear.\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\nSHORT DYNAMICS & RISK MANAGEMENT  \n\u2022 Short Interest & Squeeze Considerations:  \n\u2003\u2013 Elevated bullish positioning increases the risk of a short squeeze if unexpected catalyst news forces a quick reversal.  \n\u2022 Recommended Instruments & Positioning:  \n\u2003\u2013 Instrument: Initiate a short position using carefully sized put spreads on CAI stock to limit worst\u2011case exposure while capturing downside potential.  \n\u2003\u2013 Suggested Position Size: Moderate (e.g., 1\u20132% of portfolio risk) adjusted for volatility.\n\u2022 Hedge Strategies & Stop Triggers:  \n\u2003\u2013 Hedge with tight stops not solely based on price but on deteriorating fundamental signals (e.g., significant downgrade in clinical trial progress, unexpected regulatory announcements, or accounting restatements).  \n\u2003\u2013 Exit triggers: If technical support holds and volume surges coupled with solid regulatory/clinal updates appear, re\u2011evaluate and consider scaling out.\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\nACTION & CONCLUSION  \n\u2022 Recommended Action: SELL (or initiate a bearish hedge)  \n\u2022 Conviction Score: 70/100  \n\u2022 Downside Scenarios:  \n\u2003\u2013 Moderate adverse scenario: 25% drop (40% probability)  \n\u2003\u2013 Severe adverse scenario (triggered by a black swan event): 40%+ decline (15% probability)  \n\u2022 Final Bear Thesis (One Sentence):  \n\u2003\u201cCAI is overvalued and structurally fragile\u2014with opaque financials, a high\u2011risk business model in an evolving regulatory landscape, and unsustainable bullish sentiment\u2014that sets the stage for a dramatic correction should clinical or regulatory setbacks emerge.\u201d  \n\u2022 Strongest Bull Counter-Argument:  \n\u2003\u2013 Bulls point to strong market sentiment, aggressive IPO demand, and promising technology as indicators of sustained momentum, yet these factors inadequately compensate for the significant fundamental and structural uncertainties.\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n\nIn summary, while the bullish narrative argues for a continued rally based on momentum and sentiment, our multi\u2011layered risk analysis underscores that the company\u2019s unproven financial metrics, structural vulnerabilities, and pending regulatory catalysts create an asymmetric risk profile favoring a downturn. We therefore recommend a SELL position (implemented via protective short instruments) with disciplined hedging against a potential short squeeze.",
      "judge_decision": ""
    },
    "risk_debate_state": {
      "current_risky_response": "Caris Life Sciences represents an enticing high\u2010reward opportunity for aggressive investors willing to tolerate the inherent biotech uncertainty. Here\u2019s why the risks are worth taking and how aggressive risk managers can pursue significant upside:\n\n1. High\u2010Reward Opportunities & Growth Potential:\n\u2003\u2022 Caris boasts an innovative and potentially transformative oncology diagnostics and treatment platform. Breakthrough clinical data or favorable regulatory decisions could trigger a rapid re-rating of the stock.\n\u2003\u2022 With a robust pipeline and a current market price near $34.28 versus an average analyst target of $41.14 (and even higher on the upside), the stock has the potential for substantial near\u2010 to medium\u2010term appreciation.\n\u2003\u2022 Investors with a strong appetite for disruption in biotechnology could experience outsized gains if early clinical milestones and regulatory approvals unlock renewed market enthusiasm.\n\n2. Why the Risks Are Worth Taking:\n\u2003\u2022 Although traditional valuation multiples aren\u2019t established yet (P/E, P/B and other metrics are unavailable), the potential for exponential growth in biotech\u2014where a single positive catalyst can drive impressive returns\u2014makes this a compelling asymmetric risk/reward tradeoff.\n\u2003\u2022 The mixed fundamentals are a common challenge in early-stage biotech, but aggressive investors understand that groundbreaking science often comes with imperfect financial metrics initially.\n\u2003\u2022 With the potential for pivotal clinical data releases and market acceptance of its AI-powered molecular diagnostics, a successful execution would likely result in significantly higher enterprise value.\n\n3. Potential Upside Scenarios:\n\u2003\u2022 A series of positive clinical data releases will not only boost investor confidence but could lead to accelerated adoption, increased partnerships, and possibly even new indications.\n\u2003\u2022 Favorable regulatory decisions may pave the way for market expansion and further commercialization of its platform, potentially driving the stock price well above the current technical and analyst price targets.\n\u2003\u2022 Success stories in similar biotech firms have shown that once clinical and regulatory hurdles are overcome, these stocks can rally sharply, delivering returns that far outpace traditional investments.\n\n4. Risk Mitigation Strategies for Aggressive Positions:\n\u2003\u2022 Position Sizing & Scaling In: Allocate a modest 2\u20133% of the overall portfolio to CAI. Given the volatility, use incremental entry points (targeting the $33\u2013$34 range) to minimize exposure in a single trade.\n\u2003\u2022 Tight Stop Losses: Implement stop loss orders roughly 10% below your entry. This disciplined approach helps preserve capital and allows you to capture gains if the trend reverses.\n\u2003\u2022 Trailing Stops & Active Management: As the stock rallies, use trailing stops to lock in profits without completely exiting the position. Regularly reassess the position if upcoming catalysts materialize.\n\u2003\u2022 Stay Alert to Catalysts: Continuously monitor clinical trial progress, regulatory updates, and shifts in online sentiment. An aggressive trader should be prepared to adjust the position rapidly when new high-impact information emerges.\n\u2003\u2022 Diversified Exposure: While CAI offers an attractive risk/reward profile, maintain diversification within your biotech portfolio to spread the risk inherent to early-stage companies in this sector.\n\nIn summary, from an aggressive risk perspective, Caris Life Sciences\u2019 innovative pipeline and market momentum present the opportunity for a substantial payoff. Despite the underlying uncertainties of unproven financial measures and regulatory hurdles, the potential for a significant upside\u2014and the presence of clear risk mitigation strategies\u2014makes this an investment that aggressive risk managers can justify within a disciplined, carefully sized position.",
      "current_neutral_response": "Below is a balanced risk perspective for Caris Life Sciences Inc. (CAI) that considers both the potential upside from its innovative pipeline and strong market sentiment, as well as the inherent risks stemming from its unproven financial fundamentals and regulatory uncertainties.\n\n1. Objective Risk\u2011Reward Analysis\n\n\u2022 Upside Opportunity:\n\u2003 \u2013 The company\u2019s pipeline in oncology and the robust positive sentiment (analyst mean target of ~$41 versus the current ~$34.28) suggest a possibility of significant price appreciation.\n\u2003 \u2013 Upcoming clinical data releases and regulatory milestones could act as catalysts in the near\u2011 to medium\u2011term.\n\u2003 \u2013 Despite missing conventional valuation metrics (e.g., P/E), the market is pricing in growth potential, which may deliver an asymmetric risk\u2011reward profile favorable for a position sized appropriately.\n\n\u2022 Downside Risks:\n\u2003 \u2013 Key financial metrics (P/E, P/B, EV/EBITDA) are not yet established, making traditional valuation analysis challenging.\n\u2003 \u2013 Biotech investments are inherently volatile\u2014unfavorable clinical outcomes or regulatory setbacks can trigger rapid declines.\n\u2003 \u2013 The absence of proven profitability or robust financial history may lead to a re\u2011evaluation of its premium if market conditions sour.\n\u2003 \u2013 Technical indicators, while mixed, warn that buying at peaks without waiting for pullbacks may expose the position to short\u2011term corrections.\n\n2. Balanced Position Sizing Recommendations\n\n\u2022 Given the fund\u2019s size and the biotech sector\u2019s volatility, a conservative allocation of approximately 2\u20133% of the overall portfolio is recommended.\n\u2022 This modest position size enables exposure to potential upside while limiting overall exposure to unexpected adverse events.\n\u2022 Such sizing allows for flexibility, letting you scale in gradually and adjust the allocation as the risk profile evolves.\n\n3. Conditional Strategies Based on Market Scenarios\n\n\u2022 Entry Conditions:\n\u2003 \u2013 Target entries should be in the $33\u2013$34 range, which may provide a slightly lower average cost relative to recent peaks.\n\u2003 \u2013 Consider scaling in incrementally if the price finds firm technical support (for example, holding near $33) to reduce exposure at a single entry point.\n\n\u2022 Risk Mitigation:\n\u2003 \u2013 Implement a stop\u2011loss order roughly 10% below your entry price (around $29.70\u2013$30.60). This can help protect against a severe downside in the event of unforeseen negative clinical or regulatory news.\n\u2003 \u2013 Use trailing stops should the stock begin to rally, so gains are locked in as momentum builds.\n\n\u2022 Scenario Management:\n\u2003 \u2013 If upcoming clinical data or regulatory decisions signal strong positive outcomes, consider increasing exposure gradually.\n\u2003 \u2013 Conversely, if negative news arises (or if technical indicators deteriorate significantly), re\u2011evaluate the position size or consider exiting the position to limit further losses.\n\u2003 \u2013 Reassess fundamentals quarterly to update valuation assumptions and adjust risk allocation dynamically.\n\n4. Data\u2011Driven Recommendations Without Bias\n\n\u2022 Technical data fetched shows a \u201cHOLD\u201d signal based on mixed technical indicators; however, strong social sentiment and analyst price targets support a moderate\u2011to\u2011high conviction BUY.\n\u2022 Fundamentals remain a concern as many conventional metrics are not available, so the investment should be seen as higher\u2011risk with the potential for high reward if catalysts materialize.\n\u2022 The recommendation, based on the combined sentiment analysis, pipeline promise, and relative technical entry points, is to take a disciplined, risk\u2011managed BUY position using 2\u20133% of the portfolio and strict stop\u2011loss and scaling rules.\n\u2022 Continued monitoring of clinical, regulatory, and market conditions is critical. Adjust the strategy if the risk landscape shifts materially.\n\nIn summary, CAI presents a high\u2010potential but high\u2011risk opportunity. By targeting lower entry levels, allocating a modest portion of the portfolio, and employing controlled risk management strategies, you can aim to capture upside potential while keeping exposure to the significant uncertainties in the biotech sector in check.",
      "debate_start_time": 109603.543905791,
      "neutral_history": "Neutral Analyst: Below is a balanced risk perspective for Caris Life Sciences Inc. (CAI) that considers both the potential upside from its innovative pipeline and strong market sentiment, as well as the inherent risks stemming from its unproven financial fundamentals and regulatory uncertainties.\n\n1. Objective Risk\u2011Reward Analysis\n\n\u2022 Upside Opportunity:\n\u2003 \u2013 The company\u2019s pipeline in oncology and the robust positive sentiment (analyst mean target of ~$41 versus the current ~$34.28) suggest a possibility of significant price appreciation.\n\u2003 \u2013 Upcoming clinical data releases and regulatory milestones could act as catalysts in the near\u2011 to medium\u2011term.\n\u2003 \u2013 Despite missing conventional valuation metrics (e.g., P/E), the market is pricing in growth potential, which may deliver an asymmetric risk\u2011reward profile favorable for a position sized appropriately.\n\n\u2022 Downside Risks:\n\u2003 \u2013 Key financial metrics (P/E, P/B, EV/EBITDA) are not yet established, making traditional valuation analysis challenging.\n\u2003 \u2013 Biotech investments are inherently volatile\u2014unfavorable clinical outcomes or regulatory setbacks can trigger rapid declines.\n\u2003 \u2013 The absence of proven profitability or robust financial history may lead to a re\u2011evaluation of its premium if market conditions sour.\n\u2003 \u2013 Technical indicators, while mixed, warn that buying at peaks without waiting for pullbacks may expose the position to short\u2011term corrections.\n\n2. Balanced Position Sizing Recommendations\n\n\u2022 Given the fund\u2019s size and the biotech sector\u2019s volatility, a conservative allocation of approximately 2\u20133% of the overall portfolio is recommended.\n\u2022 This modest position size enables exposure to potential upside while limiting overall exposure to unexpected adverse events.\n\u2022 Such sizing allows for flexibility, letting you scale in gradually and adjust the allocation as the risk profile evolves.\n\n3. Conditional Strategies Based on Market Scenarios\n\n\u2022 Entry Conditions:\n\u2003 \u2013 Target entries should be in the $33\u2013$34 range, which may provide a slightly lower average cost relative to recent peaks.\n\u2003 \u2013 Consider scaling in incrementally if the price finds firm technical support (for example, holding near $33) to reduce exposure at a single entry point.\n\n\u2022 Risk Mitigation:\n\u2003 \u2013 Implement a stop\u2011loss order roughly 10% below your entry price (around $29.70\u2013$30.60). This can help protect against a severe downside in the event of unforeseen negative clinical or regulatory news.\n\u2003 \u2013 Use trailing stops should the stock begin to rally, so gains are locked in as momentum builds.\n\n\u2022 Scenario Management:\n\u2003 \u2013 If upcoming clinical data or regulatory decisions signal strong positive outcomes, consider increasing exposure gradually.\n\u2003 \u2013 Conversely, if negative news arises (or if technical indicators deteriorate significantly), re\u2011evaluate the position size or consider exiting the position to limit further losses.\n\u2003 \u2013 Reassess fundamentals quarterly to update valuation assumptions and adjust risk allocation dynamically.\n\n4. Data\u2011Driven Recommendations Without Bias\n\n\u2022 Technical data fetched shows a \u201cHOLD\u201d signal based on mixed technical indicators; however, strong social sentiment and analyst price targets support a moderate\u2011to\u2011high conviction BUY.\n\u2022 Fundamentals remain a concern as many conventional metrics are not available, so the investment should be seen as higher\u2011risk with the potential for high reward if catalysts materialize.\n\u2022 The recommendation, based on the combined sentiment analysis, pipeline promise, and relative technical entry points, is to take a disciplined, risk\u2011managed BUY position using 2\u20133% of the portfolio and strict stop\u2011loss and scaling rules.\n\u2022 Continued monitoring of clinical, regulatory, and market conditions is critical. Adjust the strategy if the risk landscape shifts materially.\n\nIn summary, CAI presents a high\u2010potential but high\u2011risk opportunity. By targeting lower entry levels, allocating a modest portion of the portfolio, and employing controlled risk management strategies, you can aim to capture upside potential while keeping exposure to the significant uncertainties in the biotech sector in check.",
      "safe_history": "Safe Analyst: Below is a conservative risk perspective on investing in CAI with an emphasis on protecting capital and carefully mitigating downside exposure:\n\n1. Capital Preservation Strategies\n\n\u2003\u2022 Use a cautious, measured entry: Instead of committing a large allocation, the plan already calls for a modest 2\u20133% of the total portfolio. This limited exposure helps ensure that even if the trade does not turn out as expected, the overall fund is largely preserved.\n\n\u2003\u2022 Scale into positions gradually: Rather than investing the full allocation at once, consider scaling in incrementally as the stock approaches and holds a support level\u2014optimally between $33 and $34. This staged approach helps avoid entering at a peak and reduces timing risk.\n\n\u2003\u2022 Set conservative stop\u2010loss orders: Implement a stop loss roughly 10% below the entry price (around $29.70\u2013$30.60) to limit losses in the event of an adverse move. Once the trade turns in your favor, using trailing stops can lock in gains while still giving room for further upside.\n\n2. Potential Downside Risks and Worst\u2011Case Scenarios\n\n\u2003\u2022 Unfavorable clinical outcomes or regulatory setbacks: As a biotech company with an emerging financial record, a negative clinical trial result or delay/failure in regulatory approval could sharply reduce the stock\u2019s valuation.\n\n\u2003\u2022 Lack of traditional metrics and financial weakness: With key valuation measures (such as P/E, ROA, and ROE) not yet established, there is uncertainty regarding the company\u2019s profitability. Structural weaknesses may drive volatility if investors become risk averse.\n\n\u2003\u2022 Market volatility and sentiment shifts: Biotech stocks\u2014even with bullish sentiment\u2014can be prone to large swings. A broader market rotation away from high\u2011risk sectors or sudden negative news may trigger rapid, significant losses.\n\n\u2003\u2022 Worst-case scenario: In a major negative catalyst, the stock may be driven lower toward or below the stop-loss level, potentially erasing much of the invested capital. Because fundamentals remain underdeveloped, extreme downside moves are a realistic concern.\n\n3. Risk Mitigation and Hedging Strategies\n\n\u2003\u2022 Diversification within the portfolio: Limit exposure to this single investment to avoid overconcentration in a volatile and relatively high\u2011risk biotech asset.\n\n\u2003\u2022 Use defined stop-loss and trailing stops: As noted, by setting a strict 10% stop-loss and employing trailing stops on an upward move, one can quickly exit if conditions deteriorate, thereby preserving capital.\n\n\u2003\u2022 Consider hedging with options (if internal policies allow): Depending on market conditions and the liquidity of options on CAI, buying protective puts could serve as insurance against steep declines. Alternatively, hedging with a biotech sector ETF or index could partially offset overall risk.\n\n\u2003\u2022 Continuous news and technical monitoring: Given the sensitivity of biotech stocks to clinical and regulatory news, maintain active monitoring of both catalysts and technical levels. This enables timely adjustments or exits if the risk environment shifts.\n\n4. Safe Position Sizing Recommendations\n\n\u2003\u2022 Stick to the recommended allocation of 2\u20133% of the total portfolio for a risk\u2011adjusted play. This small position size ensures that even if CAI underperforms due to the inherent uncertainties, the overall portfolio impact remains limited.\n\n\u2003\u2022 Reassess the position sizing if volatility notably increases or if the company\u2019s risk profile changes. If additional due diligence leads to greater uncertainty, consider reducing the allocation further.\n\n\u2003\u2022 Use gradual scaling: In the event of an initial dip that aligns with support levels, invest in increments rather than committing the full allocation upfront. This strategy minimizes market-timing risk and preserves capital if entry conditions worsen.\n\nSummary\n\nA conservative risk approach to CAI emphasizes limited exposure (2\u20133% of the portfolio), disciplined entry at lower price levels, and the use of stop-loss orders and hedging measures to protect against worst-case scenarios such as regulatory or clinical setbacks. Given the unproven financial metrics and inherent biotech sector volatility, sticking to these capital preservation and risk mitigation guidelines will help guard the overall fund while still allowing for participation in potential upside catalysts.",
      "history": "Risky Analyst: Caris Life Sciences represents an enticing high\u2010reward opportunity for aggressive investors willing to tolerate the inherent biotech uncertainty. Here\u2019s why the risks are worth taking and how aggressive risk managers can pursue significant upside:\n\n1. High\u2010Reward Opportunities & Growth Potential:\n\u2003\u2022 Caris boasts an innovative and potentially transformative oncology diagnostics and treatment platform. Breakthrough clinical data or favorable regulatory decisions could trigger a rapid re-rating of the stock.\n\u2003\u2022 With a robust pipeline and a current market price near $34.28 versus an average analyst target of $41.14 (and even higher on the upside), the stock has the potential for substantial near\u2010 to medium\u2010term appreciation.\n\u2003\u2022 Investors with a strong appetite for disruption in biotechnology could experience outsized gains if early clinical milestones and regulatory approvals unlock renewed market enthusiasm.\n\n2. Why the Risks Are Worth Taking:\n\u2003\u2022 Although traditional valuation multiples aren\u2019t established yet (P/E, P/B and other metrics are unavailable), the potential for exponential growth in biotech\u2014where a single positive catalyst can drive impressive returns\u2014makes this a compelling asymmetric risk/reward tradeoff.\n\u2003\u2022 The mixed fundamentals are a common challenge in early-stage biotech, but aggressive investors understand that groundbreaking science often comes with imperfect financial metrics initially.\n\u2003\u2022 With the potential for pivotal clinical data releases and market acceptance of its AI-powered molecular diagnostics, a successful execution would likely result in significantly higher enterprise value.\n\n3. Potential Upside Scenarios:\n\u2003\u2022 A series of positive clinical data releases will not only boost investor confidence but could lead to accelerated adoption, increased partnerships, and possibly even new indications.\n\u2003\u2022 Favorable regulatory decisions may pave the way for market expansion and further commercialization of its platform, potentially driving the stock price well above the current technical and analyst price targets.\n\u2003\u2022 Success stories in similar biotech firms have shown that once clinical and regulatory hurdles are overcome, these stocks can rally sharply, delivering returns that far outpace traditional investments.\n\n4. Risk Mitigation Strategies for Aggressive Positions:\n\u2003\u2022 Position Sizing & Scaling In: Allocate a modest 2\u20133% of the overall portfolio to CAI. Given the volatility, use incremental entry points (targeting the $33\u2013$34 range) to minimize exposure in a single trade.\n\u2003\u2022 Tight Stop Losses: Implement stop loss orders roughly 10% below your entry. This disciplined approach helps preserve capital and allows you to capture gains if the trend reverses.\n\u2003\u2022 Trailing Stops & Active Management: As the stock rallies, use trailing stops to lock in profits without completely exiting the position. Regularly reassess the position if upcoming catalysts materialize.\n\u2003\u2022 Stay Alert to Catalysts: Continuously monitor clinical trial progress, regulatory updates, and shifts in online sentiment. An aggressive trader should be prepared to adjust the position rapidly when new high-impact information emerges.\n\u2003\u2022 Diversified Exposure: While CAI offers an attractive risk/reward profile, maintain diversification within your biotech portfolio to spread the risk inherent to early-stage companies in this sector.\n\nIn summary, from an aggressive risk perspective, Caris Life Sciences\u2019 innovative pipeline and market momentum present the opportunity for a substantial payoff. Despite the underlying uncertainties of unproven financial measures and regulatory hurdles, the potential for a significant upside\u2014and the presence of clear risk mitigation strategies\u2014makes this an investment that aggressive risk managers can justify within a disciplined, carefully sized position.\n\nSafe Analyst: Below is a conservative risk perspective on investing in CAI with an emphasis on protecting capital and carefully mitigating downside exposure:\n\n1. Capital Preservation Strategies\n\n\u2003\u2022 Use a cautious, measured entry: Instead of committing a large allocation, the plan already calls for a modest 2\u20133% of the total portfolio. This limited exposure helps ensure that even if the trade does not turn out as expected, the overall fund is largely preserved.\n\n\u2003\u2022 Scale into positions gradually: Rather than investing the full allocation at once, consider scaling in incrementally as the stock approaches and holds a support level\u2014optimally between $33 and $34. This staged approach helps avoid entering at a peak and reduces timing risk.\n\n\u2003\u2022 Set conservative stop\u2010loss orders: Implement a stop loss roughly 10% below the entry price (around $29.70\u2013$30.60) to limit losses in the event of an adverse move. Once the trade turns in your favor, using trailing stops can lock in gains while still giving room for further upside.\n\n2. Potential Downside Risks and Worst\u2011Case Scenarios\n\n\u2003\u2022 Unfavorable clinical outcomes or regulatory setbacks: As a biotech company with an emerging financial record, a negative clinical trial result or delay/failure in regulatory approval could sharply reduce the stock\u2019s valuation.\n\n\u2003\u2022 Lack of traditional metrics and financial weakness: With key valuation measures (such as P/E, ROA, and ROE) not yet established, there is uncertainty regarding the company\u2019s profitability. Structural weaknesses may drive volatility if investors become risk averse.\n\n\u2003\u2022 Market volatility and sentiment shifts: Biotech stocks\u2014even with bullish sentiment\u2014can be prone to large swings. A broader market rotation away from high\u2011risk sectors or sudden negative news may trigger rapid, significant losses.\n\n\u2003\u2022 Worst-case scenario: In a major negative catalyst, the stock may be driven lower toward or below the stop-loss level, potentially erasing much of the invested capital. Because fundamentals remain underdeveloped, extreme downside moves are a realistic concern.\n\n3. Risk Mitigation and Hedging Strategies\n\n\u2003\u2022 Diversification within the portfolio: Limit exposure to this single investment to avoid overconcentration in a volatile and relatively high\u2011risk biotech asset.\n\n\u2003\u2022 Use defined stop-loss and trailing stops: As noted, by setting a strict 10% stop-loss and employing trailing stops on an upward move, one can quickly exit if conditions deteriorate, thereby preserving capital.\n\n\u2003\u2022 Consider hedging with options (if internal policies allow): Depending on market conditions and the liquidity of options on CAI, buying protective puts could serve as insurance against steep declines. Alternatively, hedging with a biotech sector ETF or index could partially offset overall risk.\n\n\u2003\u2022 Continuous news and technical monitoring: Given the sensitivity of biotech stocks to clinical and regulatory news, maintain active monitoring of both catalysts and technical levels. This enables timely adjustments or exits if the risk environment shifts.\n\n4. Safe Position Sizing Recommendations\n\n\u2003\u2022 Stick to the recommended allocation of 2\u20133% of the total portfolio for a risk\u2011adjusted play. This small position size ensures that even if CAI underperforms due to the inherent uncertainties, the overall portfolio impact remains limited.\n\n\u2003\u2022 Reassess the position sizing if volatility notably increases or if the company\u2019s risk profile changes. If additional due diligence leads to greater uncertainty, consider reducing the allocation further.\n\n\u2003\u2022 Use gradual scaling: In the event of an initial dip that aligns with support levels, invest in increments rather than committing the full allocation upfront. This strategy minimizes market-timing risk and preserves capital if entry conditions worsen.\n\nSummary\n\nA conservative risk approach to CAI emphasizes limited exposure (2\u20133% of the portfolio), disciplined entry at lower price levels, and the use of stop-loss orders and hedging measures to protect against worst-case scenarios such as regulatory or clinical setbacks. Given the unproven financial metrics and inherent biotech sector volatility, sticking to these capital preservation and risk mitigation guidelines will help guard the overall fund while still allowing for participation in potential upside catalysts.\n\nNeutral Analyst: Below is a balanced risk perspective for Caris Life Sciences Inc. (CAI) that considers both the potential upside from its innovative pipeline and strong market sentiment, as well as the inherent risks stemming from its unproven financial fundamentals and regulatory uncertainties.\n\n1. Objective Risk\u2011Reward Analysis\n\n\u2022 Upside Opportunity:\n\u2003 \u2013 The company\u2019s pipeline in oncology and the robust positive sentiment (analyst mean target of ~$41 versus the current ~$34.28) suggest a possibility of significant price appreciation.\n\u2003 \u2013 Upcoming clinical data releases and regulatory milestones could act as catalysts in the near\u2011 to medium\u2011term.\n\u2003 \u2013 Despite missing conventional valuation metrics (e.g., P/E), the market is pricing in growth potential, which may deliver an asymmetric risk\u2011reward profile favorable for a position sized appropriately.\n\n\u2022 Downside Risks:\n\u2003 \u2013 Key financial metrics (P/E, P/B, EV/EBITDA) are not yet established, making traditional valuation analysis challenging.\n\u2003 \u2013 Biotech investments are inherently volatile\u2014unfavorable clinical outcomes or regulatory setbacks can trigger rapid declines.\n\u2003 \u2013 The absence of proven profitability or robust financial history may lead to a re\u2011evaluation of its premium if market conditions sour.\n\u2003 \u2013 Technical indicators, while mixed, warn that buying at peaks without waiting for pullbacks may expose the position to short\u2011term corrections.\n\n2. Balanced Position Sizing Recommendations\n\n\u2022 Given the fund\u2019s size and the biotech sector\u2019s volatility, a conservative allocation of approximately 2\u20133% of the overall portfolio is recommended.\n\u2022 This modest position size enables exposure to potential upside while limiting overall exposure to unexpected adverse events.\n\u2022 Such sizing allows for flexibility, letting you scale in gradually and adjust the allocation as the risk profile evolves.\n\n3. Conditional Strategies Based on Market Scenarios\n\n\u2022 Entry Conditions:\n\u2003 \u2013 Target entries should be in the $33\u2013$34 range, which may provide a slightly lower average cost relative to recent peaks.\n\u2003 \u2013 Consider scaling in incrementally if the price finds firm technical support (for example, holding near $33) to reduce exposure at a single entry point.\n\n\u2022 Risk Mitigation:\n\u2003 \u2013 Implement a stop\u2011loss order roughly 10% below your entry price (around $29.70\u2013$30.60). This can help protect against a severe downside in the event of unforeseen negative clinical or regulatory news.\n\u2003 \u2013 Use trailing stops should the stock begin to rally, so gains are locked in as momentum builds.\n\n\u2022 Scenario Management:\n\u2003 \u2013 If upcoming clinical data or regulatory decisions signal strong positive outcomes, consider increasing exposure gradually.\n\u2003 \u2013 Conversely, if negative news arises (or if technical indicators deteriorate significantly), re\u2011evaluate the position size or consider exiting the position to limit further losses.\n\u2003 \u2013 Reassess fundamentals quarterly to update valuation assumptions and adjust risk allocation dynamically.\n\n4. Data\u2011Driven Recommendations Without Bias\n\n\u2022 Technical data fetched shows a \u201cHOLD\u201d signal based on mixed technical indicators; however, strong social sentiment and analyst price targets support a moderate\u2011to\u2011high conviction BUY.\n\u2022 Fundamentals remain a concern as many conventional metrics are not available, so the investment should be seen as higher\u2011risk with the potential for high reward if catalysts materialize.\n\u2022 The recommendation, based on the combined sentiment analysis, pipeline promise, and relative technical entry points, is to take a disciplined, risk\u2011managed BUY position using 2\u20133% of the portfolio and strict stop\u2011loss and scaling rules.\n\u2022 Continued monitoring of clinical, regulatory, and market conditions is critical. Adjust the strategy if the risk landscape shifts materially.\n\nIn summary, CAI presents a high\u2010potential but high\u2011risk opportunity. By targeting lower entry levels, allocating a modest portion of the portfolio, and employing controlled risk management strategies, you can aim to capture upside potential while keeping exposure to the significant uncertainties in the biotech sector in check.",
      "current_safe_response": "Below is a conservative risk perspective on investing in CAI with an emphasis on protecting capital and carefully mitigating downside exposure:\n\n1. Capital Preservation Strategies\n\n\u2003\u2022 Use a cautious, measured entry: Instead of committing a large allocation, the plan already calls for a modest 2\u20133% of the total portfolio. This limited exposure helps ensure that even if the trade does not turn out as expected, the overall fund is largely preserved.\n\n\u2003\u2022 Scale into positions gradually: Rather than investing the full allocation at once, consider scaling in incrementally as the stock approaches and holds a support level\u2014optimally between $33 and $34. This staged approach helps avoid entering at a peak and reduces timing risk.\n\n\u2003\u2022 Set conservative stop\u2010loss orders: Implement a stop loss roughly 10% below the entry price (around $29.70\u2013$30.60) to limit losses in the event of an adverse move. Once the trade turns in your favor, using trailing stops can lock in gains while still giving room for further upside.\n\n2. Potential Downside Risks and Worst\u2011Case Scenarios\n\n\u2003\u2022 Unfavorable clinical outcomes or regulatory setbacks: As a biotech company with an emerging financial record, a negative clinical trial result or delay/failure in regulatory approval could sharply reduce the stock\u2019s valuation.\n\n\u2003\u2022 Lack of traditional metrics and financial weakness: With key valuation measures (such as P/E, ROA, and ROE) not yet established, there is uncertainty regarding the company\u2019s profitability. Structural weaknesses may drive volatility if investors become risk averse.\n\n\u2003\u2022 Market volatility and sentiment shifts: Biotech stocks\u2014even with bullish sentiment\u2014can be prone to large swings. A broader market rotation away from high\u2011risk sectors or sudden negative news may trigger rapid, significant losses.\n\n\u2003\u2022 Worst-case scenario: In a major negative catalyst, the stock may be driven lower toward or below the stop-loss level, potentially erasing much of the invested capital. Because fundamentals remain underdeveloped, extreme downside moves are a realistic concern.\n\n3. Risk Mitigation and Hedging Strategies\n\n\u2003\u2022 Diversification within the portfolio: Limit exposure to this single investment to avoid overconcentration in a volatile and relatively high\u2011risk biotech asset.\n\n\u2003\u2022 Use defined stop-loss and trailing stops: As noted, by setting a strict 10% stop-loss and employing trailing stops on an upward move, one can quickly exit if conditions deteriorate, thereby preserving capital.\n\n\u2003\u2022 Consider hedging with options (if internal policies allow): Depending on market conditions and the liquidity of options on CAI, buying protective puts could serve as insurance against steep declines. Alternatively, hedging with a biotech sector ETF or index could partially offset overall risk.\n\n\u2003\u2022 Continuous news and technical monitoring: Given the sensitivity of biotech stocks to clinical and regulatory news, maintain active monitoring of both catalysts and technical levels. This enables timely adjustments or exits if the risk environment shifts.\n\n4. Safe Position Sizing Recommendations\n\n\u2003\u2022 Stick to the recommended allocation of 2\u20133% of the total portfolio for a risk\u2011adjusted play. This small position size ensures that even if CAI underperforms due to the inherent uncertainties, the overall portfolio impact remains limited.\n\n\u2003\u2022 Reassess the position sizing if volatility notably increases or if the company\u2019s risk profile changes. If additional due diligence leads to greater uncertainty, consider reducing the allocation further.\n\n\u2003\u2022 Use gradual scaling: In the event of an initial dip that aligns with support levels, invest in increments rather than committing the full allocation upfront. This strategy minimizes market-timing risk and preserves capital if entry conditions worsen.\n\nSummary\n\nA conservative risk approach to CAI emphasizes limited exposure (2\u20133% of the portfolio), disciplined entry at lower price levels, and the use of stop-loss orders and hedging measures to protect against worst-case scenarios such as regulatory or clinical setbacks. Given the unproven financial metrics and inherent biotech sector volatility, sticking to these capital preservation and risk mitigation guidelines will help guard the overall fund while still allowing for participation in potential upside catalysts.",
      "risky_history": "Risky Analyst: Caris Life Sciences represents an enticing high\u2010reward opportunity for aggressive investors willing to tolerate the inherent biotech uncertainty. Here\u2019s why the risks are worth taking and how aggressive risk managers can pursue significant upside:\n\n1. High\u2010Reward Opportunities & Growth Potential:\n\u2003\u2022 Caris boasts an innovative and potentially transformative oncology diagnostics and treatment platform. Breakthrough clinical data or favorable regulatory decisions could trigger a rapid re-rating of the stock.\n\u2003\u2022 With a robust pipeline and a current market price near $34.28 versus an average analyst target of $41.14 (and even higher on the upside), the stock has the potential for substantial near\u2010 to medium\u2010term appreciation.\n\u2003\u2022 Investors with a strong appetite for disruption in biotechnology could experience outsized gains if early clinical milestones and regulatory approvals unlock renewed market enthusiasm.\n\n2. Why the Risks Are Worth Taking:\n\u2003\u2022 Although traditional valuation multiples aren\u2019t established yet (P/E, P/B and other metrics are unavailable), the potential for exponential growth in biotech\u2014where a single positive catalyst can drive impressive returns\u2014makes this a compelling asymmetric risk/reward tradeoff.\n\u2003\u2022 The mixed fundamentals are a common challenge in early-stage biotech, but aggressive investors understand that groundbreaking science often comes with imperfect financial metrics initially.\n\u2003\u2022 With the potential for pivotal clinical data releases and market acceptance of its AI-powered molecular diagnostics, a successful execution would likely result in significantly higher enterprise value.\n\n3. Potential Upside Scenarios:\n\u2003\u2022 A series of positive clinical data releases will not only boost investor confidence but could lead to accelerated adoption, increased partnerships, and possibly even new indications.\n\u2003\u2022 Favorable regulatory decisions may pave the way for market expansion and further commercialization of its platform, potentially driving the stock price well above the current technical and analyst price targets.\n\u2003\u2022 Success stories in similar biotech firms have shown that once clinical and regulatory hurdles are overcome, these stocks can rally sharply, delivering returns that far outpace traditional investments.\n\n4. Risk Mitigation Strategies for Aggressive Positions:\n\u2003\u2022 Position Sizing & Scaling In: Allocate a modest 2\u20133% of the overall portfolio to CAI. Given the volatility, use incremental entry points (targeting the $33\u2013$34 range) to minimize exposure in a single trade.\n\u2003\u2022 Tight Stop Losses: Implement stop loss orders roughly 10% below your entry. This disciplined approach helps preserve capital and allows you to capture gains if the trend reverses.\n\u2003\u2022 Trailing Stops & Active Management: As the stock rallies, use trailing stops to lock in profits without completely exiting the position. Regularly reassess the position if upcoming catalysts materialize.\n\u2003\u2022 Stay Alert to Catalysts: Continuously monitor clinical trial progress, regulatory updates, and shifts in online sentiment. An aggressive trader should be prepared to adjust the position rapidly when new high-impact information emerges.\n\u2003\u2022 Diversified Exposure: While CAI offers an attractive risk/reward profile, maintain diversification within your biotech portfolio to spread the risk inherent to early-stage companies in this sector.\n\nIn summary, from an aggressive risk perspective, Caris Life Sciences\u2019 innovative pipeline and market momentum present the opportunity for a substantial payoff. Despite the underlying uncertainties of unproven financial measures and regulatory hurdles, the potential for a significant upside\u2014and the presence of clear risk mitigation strategies\u2014makes this an investment that aggressive risk managers can justify within a disciplined, carefully sized position.",
      "shared_context": {
        "investment_plan": "Below is the comprehensive, actionable investment plan for CAI that blends the bullish recognition of a promising pipeline and strong market sentiment with the bear concerns regarding unproven financial metrics and regulatory uncertainties.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n1. Investment Recommendation\n\n\u2022 Recommendation: BUY  \n\u2022 Confidence Level: Moderate-to-High  \n\u2022 Rationale: Although the fundamental metrics are still developing, the company\u2019s innovative clinical pipeline and strong bullish sentiment (both online and from analyst price targets with a mean of $41.14 versus the current ~$34.28) create a compelling upside. We acknowledge the downside risks noted by bearish arguments; however, for a $10B fund, a risk\u2011adjusted buy using disciplined risk management is appropriate.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n2. Position Sizing\n\n\u2022 Recommended Allocation: 2\u20133% of the portfolio  \n\u2022 Rationale: Given the asymmetric risk\u2013reward tradeoff and the biotech sector\u2019s volatility, a modest position will allow exposure to potential upside while keeping overall fund risk in check.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n3. Entry Strategy\n\n\u2022 Entry Price Range: Target initial entries between $33 and $34  \n\u2022 Conditions:  \n\u2003 \u2013 Wait for a slight pullback or stabilization near this range to avoid paying too close to recent highs.  \n\u2003 \u2013 Consider scaling in incrementally if the price shows solid support levels (e.g., holding near $33).\n\u2022 Rationale: This conservative entry zone aims to capture potential upward momentum while minimizing downside risk.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n4. Risk Management\n\n\u2022 Stop Loss Level: Approximately 10% below the entry price (around $29.70\u2013$30.60)  \n\u2022 Protective Measures:  \n\u2003 \u2013 Use trailing stops if the stock moves strongly upward to lock in gains.  \n\u2003 \u2013 Monitor liquidity and news flow closely given the sensitivity of biotech stocks.\n\u2022 Rationale: This stop-loss helps limit losses in a scenario where the company\u2019s unproven financial metrics or regulatory setbacks trigger a price decline.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n5. Time Horizon\n\n\u2022 Medium-Term Focus: Expect a time horizon of several weeks to a few months  \n\u2022 Rationale: The investment thesis leans on near- to medium-term clinical trial data, regulatory updates, and improvements in sentiment driving the stock from current levels toward the analyst mean target.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n6. Key Catalysts\n\n\u2022 Clinical Data Releases: Positive results from ongoing or upcoming studies could unlock valuation upside.  \n\u2022 Regulatory Decisions: Favorable regulatory approvals or new indications for their diagnostics platform may further boost investor confidence.  \n\u2022 Pipeline Progress: Additional news regarding expansion or commercialization of innovative cancer care solutions.\n\u2022 Market Sentiment Reinforcement: Continued bullish technical and social media sentiment sustaining momentum.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n7. Major Risks\n\n\u2022 Unfavorable Clinical/Regulatory Outcomes: Negative trial results or regulatory setbacks could quickly undermine the stock\u2019s momentum.  \n\u2022 Structural Vulnerabilities: Continued lack of traditional financial strength and profitability might become an issue as the stock matures.  \n\u2022 Market Volatility: Sudden shifts in biotech investor sentiment, including the possibility of a short squeeze if bearish positions unravel.\n\u2022 Inadequate Data Depth: Limited conventional metrics still leave aspects of the company\u2019s performance unproven.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n8. Synthesis & Final Thoughts\n\nThe bull side makes a strong case that CAI\u2019s innovative pipeline, combined with robust social sentiment and attractive analyst price targets, offers a lucrative growth opportunity. Meanwhile, the bear argument reminds us that the company forfeits traditional financial robustness and carries significant regulatory risk. Balancing these views has led to a measured BUY recommendation with a targeted entry strategy and disciplined risk management.\n\nBy allocating a modest portfolio percentage, entering at support levels, and using a 10% stop loss, we position ourselves to capture the upside from potential clinical and regulatory catalysts while protecting against downside scenarios. This plan enables the fund to participate in the potential rally driven by positive industry sentiment, yet remain safeguarded against unexpected volatility.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\nAction Steps:\n\n1. Monitor CAI price action to enter between $33\u2013$34.\n2. Scale in gradually if technical support holds.\n3. Set stop-loss orders around 10% below the entry level.\n4. Keep a close watch on upcoming clinical and regulatory news.\n5. Reassess position sizing if both bullish catalysts and downside risks materially evolve.\n\nThis balanced approach builds in both the potential gains from innovation and market excitement as well as safeguards against the risks highlighted by the bearish analysis.",
        "trader_decision": "",
        "market_report": "\ud83d\udcca TECHNICAL ANALYSIS: CAI\n\u26a1 Indicators calculated in 2.744s (Async Ultra-Fast Mode)\n============================================================\n\n\ud83d\udcc8 CURRENT PRICE ACTION:\n  Price: $34.28\n  Volume: 1,833,100\n  Day Range: $33.02 - $39.80\n\n============================================================\n\ud83d\udd0d TECHNICAL SIGNAL:\n\ud83d\udfe1 HOLD - Mixed technical signals\n  \u26a0\ufe0f Limited indicator data available\n\n\u26a1 Report generated 2025-08-13 18:32:35\n\ud83d\udcca Total indicators analyzed: 0",
        "sentiment_report": "### Social Media Analysis for CAI\n\n1. **Overall Sentiment Score**: \n   - Considering the sentiment from both Twitter and StockTwits, we have:\n     - Twitter: 1.0 (bullish)\n     - StockTwits: 1.0 (bullish)\n   - Since both sources indicate a strong bullish sentiment, the average sentiment score is approximately **1.0**.\n\n2. **Confidence Level**: \n   - Given the high confidence level from StockTwits (available data), but low confidence from Twitter (due to a single mention), the adjusted confidence level is **Medium**. This is because while StockTwits shows strong sentiment, the lack of data from Reddit and low mentions on Twitter affect overall reliability.\n\n3. **Sentiment Trend**: \n   - With both available platforms reporting a consistent bullish sentiment score of 1.0, we can classify the sentiment trend as **Stable**.\n\n4. **Top 3 Key Insights**:\n   - **Insight 1**: The overall sentiment from the available data is strongly bullish, indicative of positive market perception towards CAI.\n   - **Insight 2**: StockTwits shows a high engagement level with 30 messages, where 63.3% of those are bullish, reinforcing a favorable outlook from this platform.\n   - **Insight 3**: Data from Reddit is unavailable, which limits the completeness of sentiment analysis. Therefore, further research could benefit from monitoring additional platforms for a well-rounded view.\n\n5. **Trading Signal**: \n   - **BUY**: The strong bullish sentiment across the data, particularly in StockTwits and the existing positive sentiment from Twitter, suggests that market participants are optimistic about CAI's prospects. Given the high bullish percentage from StockTwits and the consistent sentiment score of 1.0, traders may consider taking a position in CAI.\n\n### Summary\nOverall, the sentiment towards CAI is bullish with a stable trend and medium confidence due to limited data sources. The absence of Reddit data might affect the analytical depth, but the current sentiment from Twitter and StockTwits strongly suggests a favorable environment for investors. Thus, the recommendation is to BUY based on prevailing positive sentiment.",
        "news_report": "# NEWS DATA COLLECTION - CAI\n\nGenerated: 2025-08-13 18:32:45\nTrade Date: 2025-08-13\n\n## COLLECTION METRICS\n- Total Articles: 50\n- Serper: 50 articles\n- Finnhub: 0 articles\n- Collection Time: 12.256s\n\n## RAW ARTICLE DATA\n\n### Article 1\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 2\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 3\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 4\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 5\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: Jun 17, 2025\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 6\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 7\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 8\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: Jun 18, 2025\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 9\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: Jun 18, 2025\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 10\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: Jun 18, 2025\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 11\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 12\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 13\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 14\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 15\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: 1 month ago\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 16\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 17\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 18\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: 1 month ago\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 19\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: 1 month ago\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 20\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: 1 month ago\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 21\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 22\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 23\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 24\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 25\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: 1 month ago\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 26\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 27\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 28\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: 1 month ago\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 29\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: 1 month ago\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 30\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: 1 month ago\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 31\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 32\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 33\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 34\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 35\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: Jun 17, 2025\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 36\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 37\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 38\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: Jun 18, 2025\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 39\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: Jun 18, 2025\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 40\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: Jun 18, 2025\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n### Article 41\nTitle: New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\nSource: Stock Titan\nDate: 13 hours ago\nURL: https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\nContent: Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\n\n### Article 42\nTitle: Caris Life Sciences Surges 8.15% on Intraday Rally \u2013 What\u2019s Fueling the Momentum?\nSource: AInvest\nDate: 1 day ago\nURL: https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\nContent: Summary \u2022. Caris Life Sciences \u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \u2022 Intraday range spans $29.74 to...\n\n### Article 43\nTitle: BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\nSource: AASTOCKS.com\nDate: 2 days ago\nURL: https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\nContent: Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\n\n### Article 44\nTitle: Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\nSource: Nasdaq\nDate: 1 month ago\nURL: https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\nContent: John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\n\n### Article 45\nTitle: CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\nSource: renaissancecapital.com\nDate: Jun 17, 2025\nURL: https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\nContent: Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\n\n### Article 46\nTitle: Should You Buy Caris Life Sciences Stock After The CAI IPO?\nSource: Barchart.com\nDate: 1 month ago\nURL: https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\nContent: Shares of the company are up almost 30% from its IPO price.\n\n### Article 47\nTitle: Wolfe Research initiates Caris Life Sciences stock with Outperform rating\nSource: Investing.com\nDate: 1 month ago\nURL: https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\nContent: Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\n\n### Article 48\nTitle: Caris Life Sciences trades higher on market debut (CAI)\nSource: Seeking Alpha\nDate: Jun 18, 2025\nURL: https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\nContent: Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\n\n### Article 49\nTitle: Caris Life Sciences Shares Climb After $494 Million IPO\nSource: Bloomberg.com\nDate: Jun 18, 2025\nURL: https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\nContent: Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\n\n### Article 50\nTitle: Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\nSource: Fast Company\nDate: Jun 18, 2025\nURL: https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\nContent: The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\n\n## STRUCTURED DATA\n\n```json\n{\n  \"company\": \"CAI\",\n  \"date\": \"2025-08-13\",\n  \"total\": 50,\n  \"articles\": [\n    {\n      \"index\": 1,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAFwAAABcCAMAAADUMSJqAAAAYFBMVEU1hpj///8Seozl8PImgJOrx80Id4sug5YgfpL///319/g1hpbE19vf6+2Grrm40dZ/rbjU4ebN3uKgw8ljnKuSu8Tv9/g/i5tzp7FSlaNbmKaavsaLs7z4/f1Kjp8if48IA8d0AAACHUlEQVRoge2W0ZaCIBCGRRFGydXMNCvz/d9yYdAQa8/Z8Xq+i1LBn9+ZYTRJGIZhGIZhGIZhtASQIPXHdROfOojSkDT1uaraSwfxrfJ6jy78WBqSutT5JBaqLo2G+hq23t2UXv1f2kAjRFEUq3y9MabtUOTTThRZupf4mzQXMdUQxjIhcojEBUUc9toieydR3+xpuX1KmrhsBAakzLvx3rTuMKRwPrvzhzzq3EwY7XqWrsjgnonnW0vf8UmmEBeDT/Zfcbig8cc6X5tLqA5ofZzCcjRxNaHvTc5CDPRrTcIcxAlh0Z2bPdmbjfkYhHpNcdg2FHH5EDvjATOE4nxPoIjDyRv7tL3WaF253261ThI/+9r7Im4kmn5d3W+76pHE28hXNIQRa1WKKV9rnySOObvOX5zrHtc1PjonoItLfOhKfYrL55JJPWDHfBmyeOJL+UtcFBq/KQBVbyqKJJ5iMfTzW10OeOh6rYuGw+/ThC6Ofc/ON35j6vQqUB2qfa/MJVl8KUYxPW0AQI2t3zF25+4pDV08SZY3XNHmuGEKcZHrkhHYeYniS19dVrD9txAvPfpIrGBKS3XAuRz7jbhwHTbFrlArueBLx3ZeWstF77remM/us/HGw6vUb4fsiLhJYKgX91Vjq1LmU1mWp3kzJ7MXxE0nvaUifFp4b+l4a5puSLHKQVmiPuwuKL38E7WTYx9qDMMwDMMwDMMc5Rdp+ha7HdJwqgAAAABJRU5ErkJggg==\"\n      }\n    },\n    {\n      \"index\": 2,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 3,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 4,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 5,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"Jun 17, 2025\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 6,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 7,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 8,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 9,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 10,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 11,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 1,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 12,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 2,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 13,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 3,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 14,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 4,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 15,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 5,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 16,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 6,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 17,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 7,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 18,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 8,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 19,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 9,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 20,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 10,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 21,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 1,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 22,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 2,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 23,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 3,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 24,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 4,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 25,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 5,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 26,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 6,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 27,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 7,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 28,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 8,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 29,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 9,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 30,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 10,\n        \"image_url\": \"\"\n      }\n    },\n    {\n      \"index\": 31,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/png;base64,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\"\n      }\n    },\n    {\n      \"index\": 32,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 33,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wCEAAkGBwgHBgkIBwgKCgkLDRYPDQwMDRsUFRAWIB0iIiAdHx8kKDQsJCYxJx8fLT0tMTU3Ojo6Iys/RD84QzQ5OjcBCgoKDQwNGg8PGjclHyU3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3N//AABEIAFwAXAMBIgACEQEDEQH/xAAbAAACAgMBAAAAAAAAAAAAAAAEBQMGAQIHAP/EADsQAAIBAwIDBQUECAcAAAAAAAECAwAEERIhBTFBBhMiUWEUcYGRoTKxssEjQlJiotHh8AcVJHJzgpL/xAAZAQADAQEBAAAAAAAAAAAAAAACBAUDAQD/xAAjEQACAgICAwACAwAAAAAAAAABAgADBBEhMRJBURMyBSJh/9oADAMBAAIRAxEAPwBS2r9U1HIZAKgW7jkAMUqOPNWzW3tGdidvOvT08sp67VLkFdwPWo8qwzgGvawOmK5O6nmiUjYVroAXOcYqQuuOeK1SGSY/okZ164BNcJA7nQpPQknALSG64skVwodGjfSOmrGd/rUXF+HmxuWWMtoPLJzTTs3bpHxTv5sxrApI1bZJGMf35URxtre4jPjU+RzzqbfktXePE8S3g4K30EONH0ZVlfowz61hiBuo3oiFQfFjIrZ0U9OdUVYMNiR3Q1uVPqB605HGazlaxNZZfIrUWYxvmi3Bj3ivZDhKzfo+GGMnZXjue5b/AMtgfKhouxt4YZGtuI39mF3C3RSVT7quTT3IUpcR94p6PFkfP+lRQW9rcloIYGiLDxezuQp88g4pbzI53GBWDxrmU3/I+00GkILS7U8sqyE/EeH61Y07NoIx7RIzSgDUE2XPXHnTq24dDw+MJBknJEjE7t6/CiJzhvUdam35zsdJxKuNgVry43EcfC7a0d3WMEgjSW3x86nZhHE+B9rnRE65oZo8qRnpSjWM/LGVqqq0H9RqQcOQyqoLbE6mPoOlJeOd0raZIU1vKyghQGCgDrT+Ii2twoG+nBqu8VjM9wHbfT99FX+010eYDbyQooRWfB/a3qWTw8udAMjJvipbachtEgyM8+tVKL9DxaQ8/BLH8lffuHRjIrbQKGtuIWM7Ygu4XJ/V1YPyo4LkZG9PSHLaba3kG0SAjyU4/hA++mHCLRIxPNvr2X7TEYPoSfKhm821afVdYPuIH505srcR2SeIZPiIAxzqflsBXr7H6AfOASKVdj50PIfOjbldzSniV1FZWstzcNiKJSzH0qRok6EuVka2Zu4GnNCNsTVZse26z3aJNaiO3ZgusPll6ZI/v41aZD4sYFa2UPVrzEPHyK7t+B3qCT5xS6aHOaaSbg+lDOmV5jehHEb3EF3Bnp5nNAFND1YJ4s5pZcRgnOK3VoDCRC3sL4iK5t7eSfGQWhGWHow6+8VmPs3w/TtDPFv9hJnx+KvWyBZVOATkc6dtLatgg2qbcio/nT1NrEa3IObjIjbA7lq9mT7aZjZtzoOk59cbH41YIistsjjkRyqqrJYh9CyWoc8gLwhjTzgsqRpJAmrOdS6pC+fPBJoMpfJN/JhWNTN1HttVO7dWs112fuYrZSzAqxUcyAQT91Xi5iGMk79aUXMIJNTUbwcN8lKsCxCh9zjPBOHz8QvYreFTjUO8bGyL1Jrqb4JOORqWaEd06L4NYIJUfWkCy8asY1jubeO/VNu+hcJI3vU7Z9xpu+45R31qdxKFxAezv3qMZzsSaq3aPtPHwiZbdIjNORkrqwFHqac23FUu5e4FreRy4JIkgYBds7ty+tc07XwTjtFcl0Y94VMe2cjAG1Fi0BrNWQs7LZKfKr7L5wXi8PGLAXMaFGDFXQnOk7deuxFenALbUv7I8MmsOE/6kFZZnMhQjdRgAA+u2aYzIV3GKytCrYQvUax2d6VazuDquHGKma9VGKkrscb1jAZh5+lLpRed6+lFYajghj/Ot8fsxH+R5CzobWyON4pSvkknh/FUsAFlMkqPKpX9Vlzn0zp/OtYysi6kdXP+wY+Y3rZtJO6p/wBcjPxrdwDE6zG7XUd3nuWzgAsM7jNDuhzgio+GRzG6UxQu2PtHXkYobjfEpLR9Hs0wBcKXA2AzvUu5AjajlILN4rPXCgHHWhJEz7ztTq4iRh3iYKlRpIpVF+kdpQOZKxj7zWXUarfY3AHTBIPTY0DNABJq0jPMGmt1H3U2OeR9agljwPWiBjIIi3ORjqedQlgMq65AoqRArg9DQt/J3UXeBM5OkHpmtUUsdCDZYFGzAJymWSNeY6HcUKYHGyu+B5kmp3kXm0L5PUjbPyNQd66nEiQZ/wCTTt7i1Uq0CDUgX2ta+zOkd4JMERRn95ZMD64rAWJTqUSp+8inHz5GpbqwiWD2jJLj0H4savrUXD7RLuN21yRsDgFW1H+LNG3yZofkMgnEFhcNavqYMpYjY43pnCLa7tw8pU5Xxaxj51XY7uaz4itqG72N8hu93yPhgfSnHFpDacMnljAPdpkK3I1Aza2/OCPcY3x/sDm4Re2cp9hbvbGZSQjb6D6Gl09hx6CMC24agCgAM0yk6fIDz9a34TcXRu7a49rnxI6o0QI7vSemMVcZ1BhDZOcdDRXbpA3zDGVYp1OW8W49e2DiG84aYyOrnb58jSe57R3UpXutKdCMc66B/iBaxS8BSSRdTq64Px/rXPbe1iBJAOffTuIK7U8tQmyrCOJtFcX0w8cpCnoqii4by5ht5oUnbRMDqyvmAOfMH4VGsCCRlGRjfOedTRoMtufDj60+qgdRR7Gb9jB1t3A+1sB+1n8q2UPjZpB7lJFTR4xy+pqdYgVB1vv+8aICZEz/2Q==\"\n      }\n    },\n    {\n      \"index\": 34,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 35,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"Jun 17, 2025\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 36,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 37,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 38,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 39,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 40,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 41,\n      \"api_source\": \"serper\",\n      \"title\": \"New Breast Cancer Study Reveals Which Drug Works Best for Different Patient Groups\",\n      \"source\": \"Stock Titan\",\n      \"date\": \"13 hours ago\",\n      \"url\": \"https://www.stocktitan.net/news/CAI/new-study-from-caris-life-sciences-validates-optimal-sequencing-in-j7xlymxh1wcq.html\",\n      \"full_content\": \"Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/png;base64,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\"\n      }\n    },\n    {\n      \"index\": 42,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Surges 8.15% on Intraday Rally \\u2013 What\\u2019s Fueling the Momentum?\",\n      \"source\": \"AInvest\",\n      \"date\": \"1 day ago\",\n      \"url\": \"https://www.ainvest.com/news/caris-life-sciences-surges-10-biotech-sector-turmoil-fueling-rally-2508/\",\n      \"full_content\": \"Summary \\u2022. Caris Life Sciences \\u00b7 CAI. --. (CAI) surges 8.15% to $32.674, hitting its 52-week high of $33.50 \\u2022 Intraday range spans $29.74 to...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 43,\n      \"api_source\": \"serper\",\n      \"title\": \"BABA-W's Programming Prodigy Cai Jingxian Resigns: Rumor\",\n      \"source\": \"AASTOCKS.com\",\n      \"date\": \"2 days ago\",\n      \"url\": \"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1460020&catg=1\",\n      \"full_content\": \"Rumor has it that BABA-W (09988.HK)'s programming prodigy Cai Jingxian has already resigned, with his status on both Alibaba's internal and...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 44,\n      \"api_source\": \"serper\",\n      \"title\": \"Insider Purchase: See Remarks of $CAI Buys 7,500 Shares\",\n      \"source\": \"Nasdaq\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.nasdaq.com/articles/insider-purchase-see-remarks-cai-buys-7500-shares\",\n      \"full_content\": \"John Russel Denton, the See Remarks of $CAI, bought 7500 shares of the company on 06-20-2025 for an estimated $157500.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 45,\n      \"api_source\": \"serper\",\n      \"title\": \"CAI IPO News - Caris Life Sciences prices IPO at $21, above the upwardly revised range\",\n      \"source\": \"renaissancecapital.com\",\n      \"date\": \"Jun 17, 2025\",\n      \"url\": \"https://www.renaissancecapital.com/IPO-Center/News/111604/Caris-Life-Sciences-prices-IPO-at-$21-above-the-upwardly-revised-range\",\n      \"full_content\": \"Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 46,\n      \"api_source\": \"serper\",\n      \"title\": \"Should You Buy Caris Life Sciences Stock After The CAI IPO?\",\n      \"source\": \"Barchart.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.barchart.com/story/news/33006795/should-you-buy-caris-life-sciences-stock-after-the-cai-ipo\",\n      \"full_content\": \"Shares of the company are up almost 30% from its IPO price.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 47,\n      \"api_source\": \"serper\",\n      \"title\": \"Wolfe Research initiates Caris Life Sciences stock with Outperform rating\",\n      \"source\": \"Investing.com\",\n      \"date\": \"1 month ago\",\n      \"url\": \"https://www.investing.com/news/analyst-ratings/wolfe-research-initiates-caris-life-sciences-stock-with-outperform-rating-93CH-4133498\",\n      \"full_content\": \"Wolfe Research initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with an Outperform rating and a $32.00 price target on Monday.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wCEAAkGBwgHBgkIBwgKCgkLDRYPDQwMDRsUFRAWIB0iIiAdHx8kKDQsJCYxJx8fLT0tMTU3Ojo6Iys/RD84QzQ5OjcBCgoKDQwNGg8PGjclHyU3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3N//AABEIAFwAXAMBIgACEQEDEQH/xAAcAAABBAMBAAAAAAAAAAAAAAAGAwQFBwECCAD/xAA6EAACAQMCBAMFBAkFAQAAAAABAgMABBEFIQYSEzFBUWEUIjJxgQeRobEVI0JSYnLB0eEkJkOS8Rb/xAAZAQACAwEAAAAAAAAAAAAAAAACAwABBAX/xAAhEQACAgEEAwEBAAAAAAAAAAAAAQIRAxITITEiQVEEFP/aAAwDAQACEQMRAD8A247thLw5Z3bQgS21whIX6r/WnP2f3xjSTnzyM4B+oP8Aan/GEf8AtO5Icc0aiTcZ+EjY/lQtwpqcHReNsI5IYetGILQmjSOaC4XBTm95fBsjH5kUlYxMNTJPgSPp4VHWusJHaGO73RRkMPKpaO/j9r5REyqVB6nMO9QuyI4z/wBPoR7j31Bx6tmnfBl+Op085ClVz45xvUvq+mjVOHb+MDJkizH/ADLuPxqteAtVX9MrHLJyZUnlz8bY2GKonTsuzv2rBzSNlOssAIbJUYNYW9t32WRaGhlm7Bj417LD9kGthhhkbikbuTpR7bMe1VRBTqlR8BrHtaeINMVuZMYY5FbC4HitXTJqKLv9fk1Xh19GQFppeVg5lwDysDg0PW2n61b3CYs5H97H6shwT8wcULQXV0ko6UhEu+y+GdqJ9D1KXTEQxL025ueRnb4z60XYNUTja/rCFYmsVRFYBjLt2Oe9FHBNvq2u3k+oatcdLSbXc9HbrP4Ip8vM+oFDH/13spluIGhikYZkWNSc+uCSM/QVIaVxZrd7Z+0WV/FPEDhkZUR0PqD+YJqwaS7Rbz6zIbZWsbeJY1yOWSQKeUfu+H30nbvpTRNPbSWpYEF3BXIJ8z99VA+q65Iga4Vg7ElnZecD7tsU70y8nkv2lEUZeSMxSCJgI51P7LAnGfI1l3ZRdM3fzxmrTLvs1DRc2BhhSU2k2suSFMZPihxUVwzDJbxKntssgAJaGZMFfLBog6gGxIFOi7ViJRUXRGrps9u4aG7PINyrjw+YqM1/VTahCF5mdsAZwAB33qcv5wkZXONssfSh5ys7s0gQjtvsVHlnsflg0aFMSs9ZglIRiUYnl5WHj8/70tdasLd1CxRlXXmUyTiMkZO+CO21MpIrFWaJC8bbZZYwwG+SO+DnsduxIpzb2EgiXoXrxr44LKWPmceP+KsiOUA5Hid6ykjKcgmtMV6gGDlJuVCvgdz6161uprV2aCQoT3xTcHFezV2Qsj7L9YmTUbq5njS4MUaiMSDIUknJ+e1Gt5xFJecSxpNFbRafBCrtFHCnNI5GcsxBO22MEVUHCmrLpss6u/IJQuD6j/2jC11NBz3pDSIQqs6jIXG2/wCFHlS2E12Lwt79PosCTi+4V1SGZUhGwwKYz8TXVtdJJGWcSHYI3vZPpUG7WOpW3NbsgYDfkfBqY03WrbTdNZtM0frTJkGNjzyZxsWPc7/QA1gj5PlnRlUFaVkzycQa0vQMU0NvkF5XIAI/h8/youisFWII6uCBjJOT86GrHiY3d0IJtPu7R5RFye0oV3OebfGCRj5dqKIHjRMRfCd857mtcYKJinl18VRomm2yNnkY/PFLmNAdi3/U1nq7d8/lWwJIzgUYs43VC5IHfyrY2s4GTE4H8pootdC1fpvJZ6VdXDfCWij5gvptSv6K4hRN9J1DONx7M/8AaqomsDuT0rUrU5qdjcwhpLi2e3dRmRJEKNjwODT+14D17UdK/SWnWntUQUM0cbfrAD293x23wN6phJgtHEz9hU1wvcW2n6nE94/SRmA6xUssX8fKO5H4Vm2sXji6U0bRyhiGR1KkHPiD2rEFn7VCsio5Qk4YKSPvq34pMpPU2i9tHt+CtSsem+r2OpX0owbqSULLnGBgZBGPKlLPgi3tL6O7tZhIVAywnb3seYqiX0WURGQWs7oBksIyRj54om+yyO+n4pt10yRi0YLmJpCq8o75+h7UvxfoN6vp0EDiMK2DgbjwpvJDGd1yh80OKXaFwccyE/OkZkljGWU486bwJG/+ojOOZXX5Yb/P4U7S4DKOy+hBpm0laiYjxqmVqBr7N3MPC1szn35syNn1NFYujj4qBOGtQih022tw4HTjAx9KILe+SRgvMDmtbgI3LBn7QOELjirVerFqEFuEjRcMhY7Z9fWibgawbhrQhYXM6XEgkLdVARzZ8MHyqEGoifVLtQxUq5CnPfG1PBdMnxOd640/0NTdHWjii4qyS1mKx1SQG8soJ+U5Adc71mGWGC3W3t444I1GFjRQFH0qNNwc/EabzXYU+8TufAUt5ZS7Yaxxj0TMd7cq/LGA6+WKSGqWkF4JPZoIrhf2ggDDz3pjp2prFcrgFl8QRvT/AFHStH1aSWRzyyyoAJkbDJg528jUi2/YUqXZk6do+tFriSFo5i+01vI0bE/Q1OabajSrSRhd3VxEq5C3EgfH1xmm+l6RHaRJFE7uijYt41PRQhYuUjIPfNbMceLZjySt0ugTa4Y7gAZpISyDuRRJeaTbT5PJ02/ej2/DtQ9d6TqMUxWFRMncOv8AWjdmdoqbSbmXrYVjjOKNbWdbLT5rudh7iEjNB+lATXhkce8zEnFSH2jzyWnCAEB5erKqsfSulOT0WZIQWtC+jzx3DO6yqXO7edOmuwWKrL2PaqTivrqJuaO4kQ+YY0oup3yvzC7mz/Oa4b/K37Ozur4Xa0pVRzMxH8JpFp4Qc9RgfWqy0fijUxKsTuki47uu9TY1y8Lkfq8Yz8P+aVLFKLoOORMsXRb6GFpJ3UMiLuxO2+2KBOJeLZtC4sX2G1YQRkPLBMx5Zc+WOwoR1nX9RuQ9sZunCGDFIxgMR2JpTiid73WY5J8FjbRZx/Ln+tPx4klchWTI3LgvzhX7TeF9ZWNDeDT7kjeC7wgz5Buxo7hminQPBNHKh7MjAiuM2iTOMdqVt57i0ybW5ng3/wCKQr+VaNQlo7JZdtyKi59Y0q3lMct/AHHcBs4+eK5ct9Qv52UT6heSj917h2H3E0baBg2O6g++fyFXYqcqP//Z\"\n      }\n    },\n    {\n      \"index\": 48,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences trades higher on market debut (CAI)\",\n      \"source\": \"Seeking Alpha\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://seekingalpha.com/news/4459596-caris-life-sciences-trades-higher-on-market-debut\",\n      \"full_content\": \"Shares of Caris Life Sciences (CAI) surged 27% on their Nasdaq debut after an IPO at $21. Read more here.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 49,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences Shares Climb After $494 Million IPO\",\n      \"source\": \"Bloomberg.com\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://www.bloomberg.com/news/articles/2025-06-18/caris-life-sciences-shares-climb-after-494-million-ipo\",\n      \"full_content\": \"Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the...\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    },\n    {\n      \"index\": 50,\n      \"api_source\": \"serper\",\n      \"title\": \"Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut\",\n      \"source\": \"Fast Company\",\n      \"date\": \"Jun 18, 2025\",\n      \"url\": \"https://www.fastcompany.com/91354398/caris-life-sciences-ipo-stock-price-today-ai-cancer-care-firm-nasdaq\",\n      \"full_content\": \"The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.\",\n      \"metadata\": {\n        \"position\": 0,\n        \"image_url\": \"data:image/jpeg;base64,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\"\n      }\n    }\n  ]\n}\n```\n",
        "fundamentals_report": "\ud83d\udcca FUNDAMENTALS ANALYSIS: CAI\n\u26a1 Data fetched in 3.085s (Ultra-Fast Mode)\n============================================================\n\n\ud83c\udfe2 COMPANY PROFILE:\n  Name: Caris Life Sciences Inc\n  Industry: Biotechnology\n  Market Cap: $9,533M\n  Share Outstanding: 278M\n\n\ud83d\udcc8 KEY VALUATION METRICS:\n  P/E Ratio: N/A\n  P/B Ratio: N/A\n  EV/EBITDA: N/A\n  ROE: N/A\n  ROA: N/A\n  Debt/Equity: N/A\n\n\ud83c\udfaf PRICE TARGETS:\n  Current: $34.28\n  Mean Target: $41.14\n  Low Target: $37.71\n  High Target: $44.56\n  Analysts: 10\n\n============================================================\n\ud83d\udd0d FUNDAMENTAL SIGNAL:\n\ud83d\udfe1 HOLD - Mixed fundamentals\n  \u2705 Data fetched successfully\n\n\u26a1 Report generated 2025-08-13 18:32:36"
      },
      "parallel_execution_time": 17.86139225959778,
      "count": 2,
      "latest_speaker": "Risk Manager",
      "parallel_execution": true,
      "judge_decision": "Final Decision: BUY\n\nReasoning: After evaluating the technical, sentiment, and fundamentals analysis alongside both aggressive and conservative risk perspectives, the overall outlook supports a BUY. The strong bullish sentiment from social and analyst data, combined with a promising pipeline and multiple potential clinical and regulatory catalysts, outweigh the concerns from unproven financial metrics. By entering at a controlled price range around $33\u2013$34 with a modest position sizing (2\u20133% of the portfolio) and proper risk management (e.g., 10% stop-loss), the upside of a mean target near $41.14 appears attractive relative to the downside risk. This balanced, disciplined approach enables participation in potential gains while protecting capital against adverse events.\n\nFINAL DECISION: BUY"
    },
    "research_debate_state": {
      "current_round": 2,
      "max_rounds": 1,
      "consensus_reached": false,
      "judge_feedback": "",
      "debate_history": [
        {
          "round": 1,
          "bull": "In conclusion, while the bear\u2019s criticisms about weak conventional metrics remain valid in isolation, they are outweighed by the firm\u2019s innovative pipeline, robust sentiment, and potential for significant upside as clinical data materialize\u2014making CAI an attractive risk-adjusted BUY opportunity for our $10B fund.",
          "bear": "In summary, while the bullish narrative argues for a continued rally based on momentum and sentiment, our multi\u2011layered risk analysis underscores that the company\u2019s unproven financial metrics, structural vulnerabilities, and pending regulatory catalysts create an asymmetric risk profile favoring a downturn. We therefore recommend a SELL position (implemented via protective short instruments) with disciplined hedging against a potential short squeeze."
        }
      ]
    },
    "investment_plan": "Below is the comprehensive, actionable investment plan for CAI that blends the bullish recognition of a promising pipeline and strong market sentiment with the bear concerns regarding unproven financial metrics and regulatory uncertainties.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n1. Investment Recommendation\n\n\u2022 Recommendation: BUY  \n\u2022 Confidence Level: Moderate-to-High  \n\u2022 Rationale: Although the fundamental metrics are still developing, the company\u2019s innovative clinical pipeline and strong bullish sentiment (both online and from analyst price targets with a mean of $41.14 versus the current ~$34.28) create a compelling upside. We acknowledge the downside risks noted by bearish arguments; however, for a $10B fund, a risk\u2011adjusted buy using disciplined risk management is appropriate.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n2. Position Sizing\n\n\u2022 Recommended Allocation: 2\u20133% of the portfolio  \n\u2022 Rationale: Given the asymmetric risk\u2013reward tradeoff and the biotech sector\u2019s volatility, a modest position will allow exposure to potential upside while keeping overall fund risk in check.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n3. Entry Strategy\n\n\u2022 Entry Price Range: Target initial entries between $33 and $34  \n\u2022 Conditions:  \n\u2003 \u2013 Wait for a slight pullback or stabilization near this range to avoid paying too close to recent highs.  \n\u2003 \u2013 Consider scaling in incrementally if the price shows solid support levels (e.g., holding near $33).\n\u2022 Rationale: This conservative entry zone aims to capture potential upward momentum while minimizing downside risk.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n4. Risk Management\n\n\u2022 Stop Loss Level: Approximately 10% below the entry price (around $29.70\u2013$30.60)  \n\u2022 Protective Measures:  \n\u2003 \u2013 Use trailing stops if the stock moves strongly upward to lock in gains.  \n\u2003 \u2013 Monitor liquidity and news flow closely given the sensitivity of biotech stocks.\n\u2022 Rationale: This stop-loss helps limit losses in a scenario where the company\u2019s unproven financial metrics or regulatory setbacks trigger a price decline.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n5. Time Horizon\n\n\u2022 Medium-Term Focus: Expect a time horizon of several weeks to a few months  \n\u2022 Rationale: The investment thesis leans on near- to medium-term clinical trial data, regulatory updates, and improvements in sentiment driving the stock from current levels toward the analyst mean target.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n6. Key Catalysts\n\n\u2022 Clinical Data Releases: Positive results from ongoing or upcoming studies could unlock valuation upside.  \n\u2022 Regulatory Decisions: Favorable regulatory approvals or new indications for their diagnostics platform may further boost investor confidence.  \n\u2022 Pipeline Progress: Additional news regarding expansion or commercialization of innovative cancer care solutions.\n\u2022 Market Sentiment Reinforcement: Continued bullish technical and social media sentiment sustaining momentum.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n7. Major Risks\n\n\u2022 Unfavorable Clinical/Regulatory Outcomes: Negative trial results or regulatory setbacks could quickly undermine the stock\u2019s momentum.  \n\u2022 Structural Vulnerabilities: Continued lack of traditional financial strength and profitability might become an issue as the stock matures.  \n\u2022 Market Volatility: Sudden shifts in biotech investor sentiment, including the possibility of a short squeeze if bearish positions unravel.\n\u2022 Inadequate Data Depth: Limited conventional metrics still leave aspects of the company\u2019s performance unproven.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n8. Synthesis & Final Thoughts\n\nThe bull side makes a strong case that CAI\u2019s innovative pipeline, combined with robust social sentiment and attractive analyst price targets, offers a lucrative growth opportunity. Meanwhile, the bear argument reminds us that the company forfeits traditional financial robustness and carries significant regulatory risk. Balancing these views has led to a measured BUY recommendation with a targeted entry strategy and disciplined risk management.\n\nBy allocating a modest portfolio percentage, entering at support levels, and using a 10% stop loss, we position ourselves to capture the upside from potential clinical and regulatory catalysts while protecting against downside scenarios. This plan enables the fund to participate in the potential rally driven by positive industry sentiment, yet remain safeguarded against unexpected volatility.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\nAction Steps:\n\n1. Monitor CAI price action to enter between $33\u2013$34.\n2. Scale in gradually if technical support holds.\n3. Set stop-loss orders around 10% below the entry level.\n4. Keep a close watch on upcoming clinical and regulatory news.\n5. Reassess position sizing if both bullish catalysts and downside risks materially evolve.\n\nThis balanced approach builds in both the potential gains from innovation and market excitement as well as safeguards against the risks highlighted by the bearish analysis.",
    "trader_investment_plan": "Below is the comprehensive, actionable investment plan for CAI that blends the bullish recognition of a promising pipeline and strong market sentiment with the bear concerns regarding unproven financial metrics and regulatory uncertainties.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n1. Investment Recommendation\n\n\u2022 Recommendation: BUY  \n\u2022 Confidence Level: Moderate-to-High  \n\u2022 Rationale: Although the fundamental metrics are still developing, the company\u2019s innovative clinical pipeline and strong bullish sentiment (both online and from analyst price targets with a mean of $41.14 versus the current ~$34.28) create a compelling upside. We acknowledge the downside risks noted by bearish arguments; however, for a $10B fund, a risk\u2011adjusted buy using disciplined risk management is appropriate.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n2. Position Sizing\n\n\u2022 Recommended Allocation: 2\u20133% of the portfolio  \n\u2022 Rationale: Given the asymmetric risk\u2013reward tradeoff and the biotech sector\u2019s volatility, a modest position will allow exposure to potential upside while keeping overall fund risk in check.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n3. Entry Strategy\n\n\u2022 Entry Price Range: Target initial entries between $33 and $34  \n\u2022 Conditions:  \n\u2003 \u2013 Wait for a slight pullback or stabilization near this range to avoid paying too close to recent highs.  \n\u2003 \u2013 Consider scaling in incrementally if the price shows solid support levels (e.g., holding near $33).\n\u2022 Rationale: This conservative entry zone aims to capture potential upward momentum while minimizing downside risk.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n4. Risk Management\n\n\u2022 Stop Loss Level: Approximately 10% below the entry price (around $29.70\u2013$30.60)  \n\u2022 Protective Measures:  \n\u2003 \u2013 Use trailing stops if the stock moves strongly upward to lock in gains.  \n\u2003 \u2013 Monitor liquidity and news flow closely given the sensitivity of biotech stocks.\n\u2022 Rationale: This stop-loss helps limit losses in a scenario where the company\u2019s unproven financial metrics or regulatory setbacks trigger a price decline.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n5. Time Horizon\n\n\u2022 Medium-Term Focus: Expect a time horizon of several weeks to a few months  \n\u2022 Rationale: The investment thesis leans on near- to medium-term clinical trial data, regulatory updates, and improvements in sentiment driving the stock from current levels toward the analyst mean target.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n6. Key Catalysts\n\n\u2022 Clinical Data Releases: Positive results from ongoing or upcoming studies could unlock valuation upside.  \n\u2022 Regulatory Decisions: Favorable regulatory approvals or new indications for their diagnostics platform may further boost investor confidence.  \n\u2022 Pipeline Progress: Additional news regarding expansion or commercialization of innovative cancer care solutions.\n\u2022 Market Sentiment Reinforcement: Continued bullish technical and social media sentiment sustaining momentum.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n7. Major Risks\n\n\u2022 Unfavorable Clinical/Regulatory Outcomes: Negative trial results or regulatory setbacks could quickly undermine the stock\u2019s momentum.  \n\u2022 Structural Vulnerabilities: Continued lack of traditional financial strength and profitability might become an issue as the stock matures.  \n\u2022 Market Volatility: Sudden shifts in biotech investor sentiment, including the possibility of a short squeeze if bearish positions unravel.\n\u2022 Inadequate Data Depth: Limited conventional metrics still leave aspects of the company\u2019s performance unproven.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n8. Synthesis & Final Thoughts\n\nThe bull side makes a strong case that CAI\u2019s innovative pipeline, combined with robust social sentiment and attractive analyst price targets, offers a lucrative growth opportunity. Meanwhile, the bear argument reminds us that the company forfeits traditional financial robustness and carries significant regulatory risk. Balancing these views has led to a measured BUY recommendation with a targeted entry strategy and disciplined risk management.\n\nBy allocating a modest portfolio percentage, entering at support levels, and using a 10% stop loss, we position ourselves to capture the upside from potential clinical and regulatory catalysts while protecting against downside scenarios. This plan enables the fund to participate in the potential rally driven by positive industry sentiment, yet remain safeguarded against unexpected volatility.\n\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\nAction Steps:\n\n1. Monitor CAI price action to enter between $33\u2013$34.\n2. Scale in gradually if technical support holds.\n3. Set stop-loss orders around 10% below the entry level.\n4. Keep a close watch on upcoming clinical and regulatory news.\n5. Reassess position sizing if both bullish catalysts and downside risks materially evolve.\n\nThis balanced approach builds in both the potential gains from innovation and market excitement as well as safeguards against the risks highlighted by the bearish analysis.",
    "final_trade_decision": "FINAL DECISION: BUY\n\nBelow are the detailed execution instructions based on our comprehensive analysis and risk management parameters:\n\n1. Trade Overview:\n\u2003\u2022 Action: Initiate a BUY position in CAI  \n\u2003\u2022 Allocation: Target ~2\u20133% of the $10B portfolio  \n\u2003\u2022 Rationale: Despite some fundamental uncertainties, CAI\u2019s promising clinical pipeline and strong bullish market sentiment combined with an attractive analyst mean price ($41.14 vs. current ~$34.28) justify a disciplined, risk\u2010controlled buy.\n\n2. Order Sizing & Execution:\n\u2003\u2022 Estimated Total Allocation: Approximately $210\u2013$315 million (using a mid-range assumption)  \n\u2003\u2003\u2013 At an average target entry price near $33.50, this implies roughly 6.3\u20139.4 million shares.  \n\u2003\u2022 Execution Plan: \n\u2003\u2003\u2013 Split the total order into four equal \u201cclips\u201d to minimize market impact and capture favorable microstructure conditions.\n\u2003\u2003\u2013 For each clip, use an aggressive limit order set between $33.00 and $34.00. Given current liquidity and tight bid/ask spreads, the aggressive limit order maximizes execution speed while protecting against overpaying.\n\u2003\u2003\u2003\u25e6 Example: First clip \u2013 Buy ~1.8\u20132.35 million shares at a limit of $33.50.\n\u2003\u2003\u2013 If CAI is highly liquid at the time, market orders may be considered for urgency, but given our target entry range, limit orders are preferred to control fill prices.\n\u2003\u2003\u2013 If liquidity appears thinner than expected, transition to a VWAP/TWAP algorithmic execution over a 15\u201320 minute window to achieve an optimal average price.\n\n3. Order Management & Risk Controls:\n\u2003\u2022 Risk Parameters:\n\u2003\u2003\u2013 Pre\u2010trade check: Confirm position sizing within fund limits.\n\u2003\u2003\u2013 Maximum slippage tolerance: Set to 0.5% above the limit price.\n\u2003\u2003\u2013 Stop-Loss: Place an initial stop-loss order at approximately 10% below the entry (around $29.70, assuming entry at $33.00) with a plan to switch to a trailing stop if the price begins to appreciate.\n\u2003\u2022 Partial Fill Strategy:\n\u2003\u2003\u2013 Monitor partial executions; adjust order sizes if market depth shifts.\n\u2003\u2003\u2013 Maintain flexibility to cancel remaining orders immediately if market conditions deteriorate rapidly or if news catalysts signal a material change.\n\n4. Monitoring Plan:\n\u2003\u2022 Real-time Fills & Slippage: Constantly track execution metrics, verifying that trades fill near the target price window.\n\u2003\u2022 Market Microstructure: Monitor bid/ask spread dynamics, depth-of-book, and incoming volume to ensure our orders do not inadvertently move the price.\n\u2003\u2022 Alerts: Set pre-defined alerts for significant price moves, breach of stop-loss levels, and achievement of profit targets.\n\u2003\u2022 Periodic Position Reviews: Reassess position size, execution performance, and risk levels, especially around clinical/regulatory news releases.\n\n5. Execution Timeframe & Confidence:\n\u2003\u2022 Execution Timeframe: Initiate order execution as soon as the price action stabilizes between $33 and $34; aim to complete the trade within a 15\u201320 minute window using the clip strategy.\n\u2003\u2022 Confidence Level: Moderate-to-High, based on the blended bullish clinical pipeline and strong market sentiment, offset by the inherent risks in CAI\u2019s financial metrics and regulatory environment.\n\nIn summary, we will execute a disciplined BUY using a clipped limit order strategy targeting the $33\u2013$34 range, with robust stop-loss and monitoring to navigate the near- to medium-term volatility while capturing the upside potential near the $41.14 target.",
    "processed_signal": "BUY"
  }
}